
(
  (S
    (NP
      (NP (JJ Differential) (JJ clinical) (NN efficacy))
      (PP (IN of)
        (NP (JJ anti-CD4) (JJ monoclonal) (NNS antibodies)))
      (PP (IN in)
        (NP (NN rat) (JJ adjuvant) (NN arthritis))))
    (VP (VBZ is)
      (VP (VBN paralleled)
        (PP (IN by)
          (NP
            (NP (JJ differential) (NN influence))
            (PP (IN on)
              (NP
                (NP
                  (NP (JJ NF-κB) (NN binding) (NN activity))
                  (CC and)
                  (NP (NN TNF-α) (NN secretion)))
                (PP (IN of)
                  (NP (NN T) (NNS cells)))))))))))

(
  (S
    (NP (NN Abstract))))

(
  (S
    (S
      (NP
        (NP (DT The) (NN aim))
        (PP (IN of)
          (NP (DT this) (NN study))))
      (VP (VBD was)
        (S
          (VP (TO to)
            (VP (VB analyze)
              (NP
                (NP (DT the) (JJ differential) (NNS effects))
                (PP (IN of)
                  (NP
                    (NP
                      (NP (CD three) (JJ anti-CD4) (JJ monoclonal) (NNS antibodies))
                      (PRN (-LRB- -LRB-)
                        (NP (NNS mAbs))
                        (-RRB- -RRB-)))
                    (-LRB- -LRB-)
                    (PP (IN with)
                      (NP (JJ distinct) (NN epitope) (NNS specifities)))
                    (-RRB- -RRB-)))
                (PP
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN treatment))
                      (PP (IN of)
                        (NP
                          (NP (NN rat) (JJ adjuvant) (NN arthritis))
                          (PRN (-LRB- -LRB-)
                            (NP (NN AA))
                            (-RRB- -RRB-))))))
                  (CC and)
                  (PP (IN on)
                    (NP
                      (NP (NN T-cell) (NN function))
                      (CC and)
                      (NP (NN signal) (NN transduction)))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Rat) (NN AA))
      (VP (VBD was)
        (ADVP (RB preventively))
        (VP (VBN treated)
          (PP (IN by)
            (NP
              (NP (JJ intraperitoneal) (NN injection))
              (PP (IN of)
                (NP (DT the) (JJ anti-CD4) (NNS mAbs)
                  (NP
                    (NP (NN W3/25))
                    (, ,)
                    (NP (NN OX35))
                    (, ,)
                    (CC and)
                    (NP (NN RIB5/2)))))))
          (PRN (-LRB- -LRB-)
            (UCP
              (PP
                (PP (IN on)
                  (NP (NNS days)
                    (QP (CD -1) (, ,) (CD 0) (, ,) (CD 3) (, ,)
                      (CC and)
                      (CD 6))))
                (, ,) (FW i.e.)
                (NP
                  (NP (CD 1) (NN day))
                  (PP (IN before)
                    (NP (NN AA) (NN induction))))
                (, ,)
                (PP (IN on)
                  (NP
                    (NP (DT the) (NN day))
                    (PP (IN of)
                      (NP (NN induction) (NN -LSB-day) (CD 0) (-RRB- -RSB-))))))
              (, ,)
              (CC and)
              (ADVP (RB thereafter)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS effects))
        (PP (IN on)
          (NP (NN T-cell) (NN reactivity)))
        (PP (IN in)
          (NP
            (NP
              (NP (FW vivo))
              (PRN (-LRB- -LRB-)
                (NP (JJ delayed-type) (NN hypersensitivity))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (ADJP (FW ex) (FW vivo))
              (PRN (-LRB- -LRB-)
                (NP (JJ ConA-induced) (NN proliferation))
                (-RRB- -RRB-)))
            (, ,)
            (CC and)
            (NP
              (ADJP (FW in) (FW vitro))
              (PRN (-LRB- -LRB-)
                (NP (JJ mixed) (NN lymphocyte) (NN culture))
                (-RRB- -RRB-))))))
      (VP (VBD were)
        (VP (VBN assessed))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The)
          (ADJP (FW in) (FW vitro))
          (NNS effects))
        (PP (IN of)
          (NP (JJ anti-CD4) (NN preincubation)))
        (PP (IN on)
          (NP
            (NP
              (ADJP
                (NP
                  (NP (NN T-cell) (NN receptor))
                  (PRN (-LRB- -LRB-)
                    (NP (NN TCR))
                    (-RRB- -RRB-)))
                (JJ /CD3-induced))
              (NN cytokine) (NN production))
            (CC and)
            (NP (NN signal) (NN transduction)))))
      (VP (VBD were)
        (ADVP (RB also))
        (VP (VBN analyzed))))
    (. .)))

(
  (S
    (SBAR (IN While)
      (S
        (NP
          (NP (JJ preventive) (NN treatment))
          (PP (IN with)
            (NP
              (NP (NN OX35))
              (CC and)
              (NP (NN W3/25)))))
        (ADVP (RB significantly))
        (VP (VBD ameliorated)
          (NP (NN AA))
          (PP (IN from)
            (NP (DT the) (NN onset))))))
    (, ,)
    (NP
      (NP (NN treatment))
      (PP (IN with)
        (NP (NN RIB5/2))))
    (ADVP (RB even))
    (VP
      (VP (VBD accelerated)
        (NP
          (NP (DT the) (NN onset))
          (PP (IN of)
            (NP (NN AA))))
        (PP (IN by)
          (NP
            (NP
              (QP (RB approximately) (CD 2))
              (NNS days))
            (PRN (-LRB- -LRB-)
              (NP (NN day) (CD 10))
              (-RRB- -RRB-)))))
      (, ,)
      (CC and)
      (VP (VBD ameliorated)
        (NP (DT the) (NN arthritis))
        (PP
          (ADVP (RB only))
          (IN in)
          (NP
            (NP (DT the) (JJ late) (NN phase))
            (PRN (-LRB- -LRB-)
              (NP (NN day) (CD 27))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Differential) (JJ clinical) (NNS effects))
        (PP (IN at)
          (NP
            (NP (DT the) (NN onset))
            (PP (IN of)
              (NP (NN AA))))))
      (VP (VBD were)
        (VP (VBN paralleled)
          (PP (IN by)
            (S
              (NP
                (NP (DT a) (JJ differential) (NN influence))
                (PP (IN of)
                  (NP (DT the) (NNS mAbs)))
                (PP (IN on)
                  (NP
                    (NP (NN T-cell) (NNS functions))
                    (, ,)
                    (NP
                      (NP (FW i.e.) (FW in) (NN comparison))
                      (PP (IN with)
                        (NP
                          (NP (NN OX35))
                          (CC and)
                          (NP (NN W3/25)))))
                    (, ,)
                    (NP (DT the) (`` ') (VBG accelerating) (`` ') (NN mAb) (NN RIB5/2)))))
              (VP
                (VP (VBD failed)
                  (S
                    (VP (TO to)
                      (VP (VB increase)
                        (NP
                          (NP
                            (NP (DT the) (JJ delayed-type) (NN hypersentivity))
                            (PRN (-LRB- -LRB-)
                              (NP (NN DTH))
                              (-RRB- -RRB-)))
                          (PP (TO to)
                            (NP (FW Mycobacterium) (FW tuberculosis))))))))
                (, ,)
                (VP (VBD increased)
                  (NP
                    (NP
                      (NP (DT the)
                        (ADJP (FW in) (FW vitro))
                        (NN tumor) (NN necrosis) (NN factor))
                      (PRN (-LRB- -LRB-)
                        (NP (NN TNF))
                        (-RRB- -RRB-)))
                    (NN -α) (NN secretion)))
                (, ,)
                (CC and)
                (VP
                  (ADVP (RBR more) (RB strongly))
                  (VBD induced)
                  (NP (JJ NF-κB) (NN binding) (NN activity))
                  (PP (IN after)
                    (NP
                      (NP (JJ anti-CD4) (NN preincubation))
                      (CC and)
                      (NP
                        (NP (JJ subsequent) (NN TCR/CD3-stimulation.))
                        (S
                          (PP (VBG Depending)
                            (PP (IN on)
                              (NP (PRP$ their) (NN epitope) (NN specificity))))
                          (, ,)
                          (NP (JJ different) (JJ anti-CD4) (NNS mAbs))
                          (ADVP (RB differentially))
                          (VP (VBP influence)
                            (NP
                              (NP (JJ individual) (JJ proinflammatory) (NNS functions))
                              (PP (IN of)
                                (NP (NN T) (NNS cells))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (JJ fine) (NN regulation))
      (VP
        (VP (MD may)
          (VP (VB explain)
            (NP
              (NP (DT the) (JJ differential) (NN efficacy))
              (PP (IN in)
                (NP
                  (NP (DT the) (NN treatment))
                  (PP (IN of)
                    (NP (NN AA))))))))
        (CC and)
        (VP (MD may)
          (VP (VB contribute)
            (PP (TO to)
              (NP
                (NP (DT the) (NN understanding))
                (PP (IN of)
                  (NP
                    (NP (JJ such) (NNS treatments))
                    (PP (IN in)
                      (NP (JJ other) (NNS immunopathologies)))))))))))
    (. .)))

(
  (S
    (NP (NN Introduction))))

(
  (S
    (S
      (NP
        (NP (JJ CD4+) (NN T) (NNS cells))
        (CC and)
        (NP (PRP$ their) (NN cytokine) (NNS products)))
      (VP (VBP play)
        (NP (DT an) (JJ important) (NN role))
        (PP (IN in)
          (NP
            (NP (JJ rheumatoid) (NN arthritis))
            (CC and)
            (NP
              (NP (JJ experimental) (NNS models))
              (PP (IN of)
                (NP (NN arthritis))))))
        (, ,)
        (S
          (ADVP (RB therefore))
          (VP (VBG representing)
            (NP
              (NP (JJ potential) (JJ therapeutic) (NNS targets))
              (CD -LSB-1) (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP (DT A) (JJ specific) (JJ therapeutic) (NN approach))
      (VP (VBZ is)
        (NP
          (NP (DT the) (JJ direct) (NN targeting))
          (PP (IN of)
            (NP (JJ CD4+) (NN T) (NNS cells)))
          (PP (IN by)
            (NP
              (NP (NN use))
              (PP (IN of)
                (NP
                  (NP
                    (NP (JJ monoclonal) (NNS antibodies))
                    (PRN (-LRB- -LRB-)
                      (NP (NNS mAbs))
                      (-RRB- -RRB-)))
                  (PP (IN against)
                    (NP (DT the) (NN CD4) (NN coreceptor))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Anti-CD4) (NNS mAbs))
      (VP (VBP induce)
        (NP (CC either)
          (NP (NN cell) (NN depletion) (NN -LSB-2) (-RRB- -RSB-))
          (CC or)
          (NP
            (NP (JJ functional) (NN inactivation))
            (PP (IN of)
              (NP (NN T) (NNS cells))))
          (NP (NN -LSB-3,4))
          (-RRB- -RSB-))
        (, ,)
        (SBAR (IN although)
          (S
            (NP
              (NP (NN activation))
              (PP (IN of)
                (NP (NN T-cell) (NNS functions))))
            (VP (VBZ has)
              (ADVP (RB also))
              (VP (VBN been)
                (VP (VBN reported)
                  (S
                    (NP (NN -LSB-5))
                    (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (JJ contrasting) (NNS effects))
      (VP (MD may)
        (VP (VB explain)
          (NP
            (NP (DT the) (NN variability))
            (PP (IN in)
              (NP
                (NP (DT the) (JJ clinical) (NN efficacy))
                (PP (IN of)
                  (NP (JJ different) (JJ anti-CD4) (NNS mAbs))))))
          (PP (IN in)
            (NP
              (NP (DT the) (NN treatment))
              (PP (IN of)
                (NP
                  (NP (JJ rheumatoid) (NN arthritis))
                  (PRN (, ,)
                    (PP (FW i.e.)
                      (NP
                        (NP (JJ promising) (JJ initial) (NN efficacy))
                        (PP (IN in)
                          (NP
                            (NP
                              (NP (JJ open) (JJ anti-CD4) (NNS trials))
                              (CD -LSB-6,7) (-RRB- -RSB-))
                            (, ,)
                            (NP
                              (NP (JJ subsequent) (JJ disappointing) (JJ double-blind) (JJ clinical) (NNS trials))
                              (PRN (-LRB- -LRB-)
                                (VP (VBN reviewed)
                                  (PP (IN in)
                                    (NP (NN -LSB-8))))
                                (-RRB- -RSB-) (-RRB- -RRB-)))
                            (, ,)
                            (CC and)
                            (, ,)
                            (ADVP (RB finally))
                            (, ,)
                            (NP
                              (NP (DT a) (NN revival))
                              (PP (IN of)
                                (NP
                                  (NP (DT the) (JJ anti-CD4) (NN treatment) (NN principle))
                                  (PP (IN with)
                                    (NP
                                      (ADJP
                                        (ADJP (JJ new))
                                        (, ,)
                                        (ADJP (JJ humanized)))
                                      (JJ anti-CD4) (NNS mAbs))))))))))
                    (NP (NN -LSB-9,10))
                    (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN focus))
        (PP (IN of)
          (NP (DT the) (JJ present) (NN study))))
      (VP (VBD was)
        (S
          (VP (TO to)
            (VP (VB analyze)
              (NP
                (NP (DT the) (NNS effects))
                (PP (IN of)
                  (NP
                    (NP (DT the) (JJ anti-CD4) (NNS mAbs))
                    (NP
                      (NP (NN W3/25))
                      (, ,)
                      (NP (NN OX35))
                      (, ,)
                      (CC and)
                      (NP (NN RIB5/2)))))
                (PP (IN in)
                  (NP
                    (NP
                      (NP (NN rat) (JJ adjuvant) (NN arthritis))
                      (PRN (-LRB- -LRB-)
                        (NP (NN AA))
                        (-RRB- -RRB-)))
                    (, ,)
                    (NP
                      (NP (DT a) (JJ well-known) (, ,) (RB clearly) (JJ CD4+) (JJ T-cell-dependent) (JJ experimental) (NN arthritis) (NN model))
                      (CD -LSB-11-13) (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS mAbs))
      (VP
        (VP (VBP target)
          (NP
            (NP (JJ different) (NNS epitopes))
            (PP (IN of)
              (NP (DT the) (NN CD4) (NN molecule)))))
        (CC and)
        (VP (VBP do) (RB not)
          (VP (VB compete)
            (PP (IN for)
              (NP (NN CD4) (NN binding) (CD -LSB-14) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP (PRP They))
      (VP (VBP are)
        (ADJP (RB equally) (JJ effective)
          (PP (IN in)
            (S
              (VP (VBG suppressing)
                (NP (NN AA))
                (PP (IN upon)
                  (NP
                    (NP (NN treatment))
                    (PP (IN of)
                      (NP
                        (NP (JJ established) (NN disease) (CD -LSB-11,12) (-RRB- -RSB-))
                        (PRN (-LRB- -LRB-)
                          (CC and)
                          (NP (NNS authors)
                            (NP (JJ own) (JJ unpublished) (NNS observations)))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (NN contrast)))
    (, ,)
    (NP
      (NP (JJ preventive) (NN treatment))
      (PP (IN with)
        (NP
          (NP (DT the) (JJ anti-CD4) (NNS mAbs))
          (NP
            (NP (NN W3/25))
            (, ,)
            (NP (NN OX35))
            (, ,)
            (CC and)
            (NP
              (NP (NN RIB5/2))
              (PRN (-LRB- -LRB-)
                (UCP
                  (PP
                    (PP (IN on)
                      (NP
                        (NP (NNS days))
                        (PP
                          (NP
                            (QP (CD -1) (, ,) (CD 0) (, ,) (CD 3) (, ,)
                              (CC and)
                              (CD 6) (, ,) (FW i.e.) (CD 1))
                            (NN day))
                          (IN before)
                          (NP (NN AA) (NN induction)))))
                    (, ,)
                    (PP (IN on)
                      (NP (DT the) (NN day)))
                    (PP (IN of)
                      (NP (NN induction) (NN -LSB-day) (CD 0)))
                    (-RRB- -RSB-))
                  (, ,)
                  (CC and)
                  (ADVP (RB thereafter)))
                (-RRB- -RRB-)))))))
    (VP (VBD had)
      (NP (JJ opposite) (NNS effects))
      (PP (IN in)
        (NP
          (NP (DT the) (NN induction) (NN phase))
          (PP (IN of)
            (NP (NN AA))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN In) (NN order)
        (S
          (VP (TO to)
            (VP (VB explain)
              (NP (DT this) (JJ differential) (NN efficacy))))))
      (, ,)
      (NP (JJ several) (NNS parameters))
      (VP (VBD were)
        (VP (VBN analyzed))))
    (. .)))

(
  (S
    (NP (NNS Methods))))

(
  (S
    (S
      (PP (IN For)
        (NP (NNS animals)))
      (, ,)
      (NP
        (NP (NN arthritis) (NN model))
        (, ,)
        (NP (NNS antibodies))
        (, ,)
        (CC and)
        (NP
          (NP (NN affinity) (NN determination))
          (PRN (-LRB- -LRB-)
            (NP (NN surface) (NN plasmon) (NN resonance))
            (-RRB- -RRB-)))
        (, ,))
      (VP (VB see)
        (NP (JJ Supplementary) (NN material))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN T-cell) (NN reactivity))
        (VP (VBD was)
          (VP (VBN measured)
            (ADVP (FW in) (FW vivo))
            (PP
              (PP (IN by)
                (NP
                  (NP (JJ delayed-type) (NN hypersensitivity))
                  (PRN (-LRB- -LRB-)
                    (NP (NN DTH))
                    (-RRB- -RRB-))))
              (CC and)
              (ADVP (FW in) (FW vitro))
              (PP (IN by)
                (NP
                  (NP (NN proliferation) (NN assay))
                  (CC or)
                  (NP (JJ mixed) (NN lymphocyte) (NN culture))))))))
      (, ,)
      (CC and)
      (S
        (NP (NNS cytokines))
        (VP (VBD were)
          (VP (VBN measured)
            (PP (IN by)
              (NP
                (NP (NN bioassay))
                (CC or)
                (NP (NN ELISA))))
            (PRN (-LRB- -LRB-)
              (S
                (VP (VB see)
                  (NP
                    (NP (JJ Supplementary) (NN material) (: ;))
                    (PP (IN for)
                      (NP
                        (NP
                          (NP (NN tumor) (NN necrosis) (NN factor))
                          (PRN (-LRB- -LRB-)
                            (NP (NN TNF))
                            (-RRB- -RRB-)))
                        (NN -α) (NN -LSB-15))))))
              (-RRB- -RSB-) (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Cells))
      (VP (VBD were)
        (VP (VBN stimulated)
          (PP (IN by)
            (NP
              (NP
                (NP (NN preincubation))
                (PP (IN with)
                  (NP (JJ anti-CD4) (NNS mAbs))))
              (CC and)
              (NP
                (NP (JJ subsequent) (NN stimulation))
                (PP (IN of)
                  (NP (NN T-cell) (NNS receptors)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NN assay))
        (PRN (-LRB- -LRB-)
          (NP (NN EMSA))
          (-RRB- -RRB-)))
      (VP (VBD was)
        (SBAR (IN as)
          (S
            (VP (VBN described)
              (PP (IN in)
                (NP (DT the) (JJ Supplementary) (NN material))))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP (JJ statistical) (NN analysis)))
    (, ,)
    (NP (PRP we))
    (VP (VBD used)
      (NP
        (NP (DT the)
          (ADJP (NN Mann–Whitney) (-LRB- -LRB-) (NN U) (-RRB- -RRB-) (JJ test/Spearman))
          (NN rank) (NN correlation))
        (PRN (-LRB- -LRB-)
          (NP (NN P) (NN ≤) (CD 0.05))
          (: ;)
          (S
            (VP (VB see)
              (NP (JJ Supplementary) (NN material))))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (NP (NNS Results))))

(
  (S
    (NP
      (NP (JJ Preventive) (NN treatment))
      (PP (IN with)
        (NP (DT the) (JJ anti-CD4) (NNS mAbs)
          (NP
            (NP (CD W3/25))
            (CC and)
            (NP (CD OX35))))))
    (VP (VBD led)
      (PP (TO to)
        (NP
          (NP (DT a)
            (ADJP
              (ADJP (JJ marked))
              (, ,)
              (ADJP (JJ significant)))
            (NN suppression))
          (PP (IN of)
            (NP
              (NP (DT the) (NN arthritis) (NN score))
              (PP (IN from)
                (NP (NN day) (CD 13) (TO to) (CD 30)))))
          (PP (IN in)
            (NP
              (NP (NN comparison))
              (PP (IN with)
                (NP
                  (NP (JJ PBS-treated) (NNS animals))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN P))
                      (: ≤)
                      (NP (CD 0.05))
                      (: ;)
                      (NP (NNP Fig.) (CD 1)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (NN contrast)))
    (, ,)
    (NP (DT the) (JJ anti-CD4) (NN mAb) (NN RIB5/2))
    (ADVP (RB significantly))
    (VP
      (VP (VBN accelerated)
        (NP
          (NP (DT the) (NN onset))
          (PP (IN of)
            (NP (DT the) (NN arthritis)))
          (PP (IN by)
            (NP
              (NP
                (QP (RB approximately) (CD 2))
                (NNS days))
              (PRN (-LRB- -LRB-)
                (NP (NN P) (NN ≤) (CD 0.01))
                (: ;)
                (NP (NNS days) (CD 11))
                (, ,)
                (NP (CD 12))
                (: ;)
                (S
                  (VP (VB see)
                    (NP (NNP Fig.) (CD 1))))
                (-RRB- -RRB-))))))
      (, ,)
      (VP (VBG resulting)
        (PP (IN in)
          (NP
            (NP (DT an) (VBN aggravated) (JJ clinical) (NN score))
            (PP (IN on)
              (NP (DT these) (NNS days))))))
      (, ,)
      (CC and)
      (VP (VBD ameliorated)
        (NP (JJ clinical) (NNS signs))
        (PP
          (ADVP (RB only))
          (IN from)
          (NP
            (NP (NN day) (CD 27))
            (PRN (-LRB- -LRB-)
              (NP (NN P) (NN ≤) (CD 0.05))
              (: ;)
              (S
                (VP (VB see)
                  (NP (NNP Fig.) (CD 1))))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (DT The) (VBG accelerating) (NN effect))
          (PP (IN of)
            (NP (DT the) (NN mAb) (NN RIB5/2))))
        (VP (VBD was)
          (VP (VBN reproduced)
            (PP (IN in)
              (NP (CD two) (JJ additional) (NN treatment) (NNS experiments))))))
      (, ,)
      (CC and)
      (S
        (NP (DT this) (NN effect))
        (VP (VBD was)
          (VP (VBN observed)
            (PP (IN despite)
              (NP
                (NP (DT a) (JJ variable) (NN onset))
                (PP (IN of)
                  (NP (NN AA)))))
            (PP (IN in)
              (NP
                (NP
                  (NP (DT the) (JJ PBS-treated) (NNS animals))
                  (PRN (-LRB- -LRB-)
                    (NP (NN day) (CD 9) (TO to) (CD 11))
                    (-RRB- -RRB-)))
                (: ;)
                (NP
                  (NP (FW i.e.))
                  (S
                    (PP (IN in)
                      (NP (DT all) (NNS experiments)))
                    (, ,)
                    (NP
                      (NP (DT the) (NN onset))
                      (PP (IN of)
                        (NP (NN AA))))
                    (VP (VBD occurred)
                      (NP
                        (NP (CD 2) (NNS days))
                        (ADJP (JJR earlier)
                          (PP (IN than)
                            (PP (IN in)
                              (NP (DT the) (NNS controls)))))))))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN In) (NN order)
        (S
          (VP (TO to)
            (VP (VB identify)
              (NP
                (NP (JJ potential) (NNS mechanisms))
                (PP (IN for)
                  (NP (DT these) (JJ differential) (NNS effects))))))))
      (, ,)
      (NP
        (NP
          (NP (DT the) (JJ molecular) (NNS properties))
          (PP (IN of)
            (NP (DT the) (NNS mAbs))))
        (CC and)
        (NP
          (NP (PRP$ their) (NN influence))
          (PP (IN on)
            (NP (NN T-cell) (NN effector) (NNS functions))))
        (ADVP
          (ADVP (FW in) (FW vivo))
          (CC and)
          (ADVP (FW in) (FW vitro))))
      (VP (VBD were)
        (VP (VBN investigated))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP
        (NP (DT the) (NN sake))
        (PP (IN of)
          (NP (NN simplicity)))))
    (, ,)
    (NP (PRP we))
    (VP (VBP refer)
      (PP (TO to)
        (NP (DT the) (NN mAb) (NN RIB5/2)))
      (PP (IN as)
        (NP
          (NP
            (NP (`` ')
              (NP (VBG accelerating))
              ('' '))
            (PRN (-LRB- -LRB-)
              (SBAR (IN although)
                (S
                  (NP (DT this) (NN term))
                  (VP (VBZ is)
                    (ADJP (JJ applicable)
                      (PP
                        (ADVP (RB only))
                        (TO to)
                        (NP
                          (NP (DT the) (NN onset))
                          (PP (IN of)
                            (NP (NN AA)))))))))
              (-RRB- -RRB-)))
          (CC and)
          (NP
            (NP (DT the) (NNS mAbs)
              (NP
                (NP (CD W3/25))
                (CC and)
                (NP (CD OX35))))
            (ADJP (RB as) (`` ') (JJ ameliorating) ('' '))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Calculation))
        (PP (IN of)
          (NP
            (NP (DT the) (NN affinity) (NN constant))
            (PRN (-LRB- -LRB-)
              (NP (NN KA))
              (-RRB- -RRB-)))))
      (VP (VBD resulted)
        (PP (IN in)
          (NP
            (NP (JJ comparable) (NNS values))
            (PP (IN for)
              (NP
                (NP
                  (NP (NN OX35))
                  (CC and)
                  (NP (NN RIB5/2)))
                (PRN (-LRB- -LRB-)
                  (VP (VB see)
                    (NP (NN Supplementary) (NN Table) (CD 1)))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP
        (NP (DT the) (NN affinity))
        (PP (IN of)
          (NP (NN W3/25))))
      (VP (VBD was)
        (ADVP (RB 50-fold))
        (NP
          (NP (DT that))
          (PP (IN for)
            (NP (DT the) (CD two) (JJ other) (NNS mAbs))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN While)
        (S
          (NP
            (NP
              (NP (DT the) (NN association) (NN rate) (NNS constants))
              (PRN (-LRB- -LRB-)
                (NP (NN kass))
                (-RRB- -RRB-)))
            (PP (IN for)
              (NP (DT all) (CD three) (NNS mAbs))))
          (VP (VBD were)
            (PP (IN within)
              (NP
                (NP (DT the) (JJ same) (NN order))
                (PP (IN of)
                  (NP (NN magnitude))))))))
      (, ,)
      (NP
        (NP (JJ striking) (NNS differences))
        (PRN (-LRB- -LRB-)
          (NP (CD up) (TO to) (RB 40-fold))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN observed)
          (PP (IN for)
            (NP
              (NP (DT the) (NN dissociation) (NN rate) (NNS constants))
              (PRN (-LRB- -LRB-)
                (NP (NN kdiss))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Thus))
      (, ,)
      (SBAR (IN although)
        (S
          (NP
            (NP (NNS differences))
            (PP (IN in)
              (NP (JJ overall) (NN affinity))))
          (VP (VBD did) (RB not)
            (VP (VBP match)
              (NP (JJ differential) (JJ clinical) (NN efficacy))))))
      (, ,)
      (NP (DT the) (VBG accelerating) (NN mAb) (NN RIB5/2))
      (VP (VBD displayed)
        (NP (DT the) (JJS highest) (NN kdiss))))
    (. .)))

(
  (S
    (S
      (NP (NN T-cell) (NN reactivity))
      (VP (VBD was)
        (VP (VBN investigated)
          (PP (IN on)
            (NP
              (NP (NN day) (CD 13))
              (PP (IN of)
                (NP (NN AA)))))
          (, ,)
          (PP (FW i.e.)))
        (SBAR
          (WHADVP (WRB when))
          (S
            (NP
              (NP (DT the) (JJ clinical) (NNS differences))
              (PP (IN between)
                (NP (DT the)
                  (ADJP
                    (ADJP (VBG accelerating))
                    (CC and)
                    (ADJP (VBG ameliorating)))
                  (JJ anti-CD4) (NNS mAbs))))
            (VP (VBD were)
              (ADJP (JJ maximal)))))))
    (. .)))

(
  (S
    (PP (VBN Compared)
      (PP (TO to)
        (NP (DT the) (JJ PBS-treated) (NN control) (NN group))))
    (, ,)
    (NP (DT the) (JJ ameliorating) (NN mAb) (NN OX35))
    (VP (VBD induced)
      (NP
        (NP (DT a) (JJ significant) (NN increase))
        (PP (IN of)
          (NP (DT the) (NN DTH))))
      (PP (IN in) (NN response) (TO to)
        (NP
          (NP (DT the) (JJ arthritogen) (NN Mycobacterium) (NN tuberculosis))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NN Supplementary))
              (NP (NNP Fig.) (CD 1)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (DT The) (JJ other) (JJ ameliorating) (JJ anti-CD4) (NN mAb))
          (, ,)
          (NP (NN W3/25))
          (, ,))
        (ADVP (RB also))
        (VP (VBD induced)
          (NP (DT an) (NN increase))))
      (, ,)
      (CC but)
      (S
        (NP (JJ statistical) (NN significance))
        (VP (VBD was) (RB not)
          (VP (VBN reached)))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP
        (NP (NN treatment))
        (PP (IN with)
          (NP
            (NP (DT the) (VBG accelerating) (JJ anti-CD4) (NN mAb))
            (, ,)
            (NP (NN RIB5/2))
            (, ,))))
      (VP (VBD had)
        (ADVP (RB virtually))
        (NP
          (NP (DT no) (NN influence))
          (PP (IN on)
            (NP (DT the) (NN DTH))))))
    (. .)))

(
  (S
    (PP (IN Upon)
      (NP
        (NP (NN stimulation))
        (PP (IN with)
          (NP
            (NP (NN concanavalin) (NN A))
            (PRN (-LRB- -LRB-)
              (NP (NN ConA))
              (-RRB- -RRB-))))))
    (, ,)
    (NP
      (NP (JJ total) (NN T) (NNS cells))
      (PP (IN from)
        (NP (JJ RIB5/2-treated) (NNS animals))))
    (VP (VBD showed)
      (NP (JJR lower) (NN proliferation) (NNS rates))
      (PP (IN than)
        (NP
          (NP (DT those))
          (PP (IN from)
            (NP
              (NP
                (ADJP
                  (ADJP (JJ W3/25-))
                  (CC or)
                  (ADJP (JJ OX35-treated)))
                (NNS rats))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN Supplementary))
                  (NP (NNP Fig.) (CD 2)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ mixed) (NN lymphocyte) (NN culture)))
      (, ,)
      (NP (NN RIB5/2))
      (VP (VBD was)
        (ADVP (RB also))
        (NP
          (NP (DT the)
            (ADJP (RBS most) (JJ potent))
            (NN inhibitor))
          (PP (IN of)
            (NP (NN T-cell) (NN activation))))
        (PP (IN in)
          (NP
            (NP (DT the) (NN case))
            (PP (IN of)
              (NP (JJ total) (NN T) (NNS cells)))))))
    (: ;)
    (S
      (ADVP (RB however))
      (, ,)
      (NP (DT this))
      (VP (VBD was) (RB not)
        (VP (VBN observed)
          (PP (IN in)
            (NP
              (NP (VBN purified) (JJ CD4+) (NN T) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN Supplementary))
                  (NP (NNP Fig.) (CD 4)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (S
        (S
          (VP (TO To)
            (VP (VB simulate)
              (NP (DT the) (JJ preventive) (JJ therapeutic) (NN application))
              (PP (IN in)
                (NP
                  (NP (NNS AA))
                  (, ,)
                  (PP (FW i.e.)
                    (NP
                      (NP (DT the) (NN activation))
                      (PP (IN of)
                        (NP (JJ CD4+) (NN T) (NNS cells)))
                      (PP (IN in)
                        (NP
                          (NP (DT the) (NN presence))
                          (PP (IN of)
                            (NP (JJ anti-CD4) (NNS mAbs))))))))))))
        (, ,)
        (NP (VBN purified) (NN spleen) (JJ CD4+) (NN T) (NNS cells))
        (VP (VBD were)
          (VP (VBN incubated)
            (PP (IN with)
              (NP (JJ anti-CD4) (NN mAb))))))
      (CC and)
      (S (, ,)
        (PP (IN after)
          (NP (NN cross-linking)))
        (, ,)
        (VP (VBN stimulated)
          (PP (IN with)
            (NP
              (NP (JJ plate-bound) (NN anti-T-cell-receptor) (-LRB- -LRB-) (NN TCR) (-RRB- -RRB-) (NN α/β) (NN mAb))
              (PRN (-LRB- -LRB-)
                (NP
                  (ADJP (RB so) (VBN called))
                  (JJ anti-CD4) (NN preincubation))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (ADVP (RB Interestingly))
    (, ,)
    (NP
      (NP (JJ anti-CD4) (NN preincubation))
      (PP (IN with)
        (NP (DT the) (VBG accelerating) (JJ anti-CD4) (NN mAb) (CD RIB5/2))))
    (VP (VBD led)
      (PP (TO to)
        (NP
          (NP (DT a)
            (ADJP (RB significantly) (JJR higher))
            (NN TNF-α) (NN secretion))
          (, ,)
          (PP (IN in)
            (NP
              (NP (NN comparison))
              (PP (CC both)
                (PP (IN with)
                  (NP (DT the) (NN isotype) (NN control)))
                (CC and)
                (PP (IN with)
                  (NP (DT the) (CD two) (JJ other) (JJ anti-CD4) (NNS mAbs))))))
          (, ,)
          (NP
            (NP
              (NP (NN W3/25))
              (CC and)
              (NP (NN OX35)))
            (PRN (-LRB- -LRB-)
              (NP (NNP Fig.) (CD 2))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Differential) (NN induction))
        (PP (IN of)
          (NP (NN TNF-α)))
        (PP (IN by)
          (NP (NN RIB5/2))))
      (VP (VBD was)
        (ADVP (RB also))
        (VP (VBN seen)
          (PP (IN after)
            (NP (NN CD4-cross-linking)))
          (PP
            (PP (IN on)
              (NP
                (NP (DT the) (JJ CD4+) (NN T-cell) (NN clone))
                (NN A2b)))
            (CC or)
            (PP (IN on)
              (NP
                (NP (JJ TCR-stimulated) (JJ CD4+) (NN T-cell) (NNS blasts))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (DT both) (NNS data) (NNS sets))
                    (VP (RB not) (VBN shown)))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (PP (IN For)
        (NP
          (NP (NN IFN-γ))
          (, ,)
          (NP (NN IL-10))
          (, ,)
          (CC and)
          (NP (NN IL-4))))
      (, ,)
      (VP (VB see)
        (NP (JJ Supplementary) (NN material))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Because)
        (S
          (NP (DT the) (CD three) (JJ anti-CD4) (NNS mAbs))
          (VP (VBP recognize)
            (NP
              (NP (JJ distinct) (NNS epitopes))
              (PP (IN of)
                (NP
                  (NP (DT the) (NN CD4) (NN molecule))
                  (, ,)
                  (SBAR
                    (WHNP (WDT which))
                    (S
                      (VP (VBZ is)
                        (VP (VBN involved)
                          (PP (IN in)
                            (NP (NN signaling) (NNS cascades)))))))))))))
      (, ,)
      (NP
        (NP (DT the) (NN influence))
        (PP (IN of)
          (NP (DT these) (NNS mAbs)))
        (PP (IN on)
          (NP (JJ early) (NN signaling) (NNS events))))
      (VP (VBD was)
        (ADVP (RB also))
        (VP (VBN investigated))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT No) (NN influence))
        (PP (IN at)
          (NP
            (NP (DT all))
            (PP (IN of)
              (NP (DT the) (JJ anti-CD4) (NNS mAbs))))))
      (VP (VBD was)
        (VP (VBN found)
          (PP (IN for)
            (NP
              (NP
                (NP (NN calcium) (NN influx))
                (PRN (-LRB- -LRB-)
                  (NP (JJ primary) (JJ CD4+) (NN spleen) (NN T) (NNS cells))
                  (-RRB- -RRB-)))
              (, ,)
              (NP
                (NP (NN phosphorylation))
                (PP (IN of)
                  (NP
                    (NP (JJ src-homology-domain-containing) (NN protein))
                    (PRN (-LRB- -LRB-)
                      (NP (NN Shc))
                      (-RRB- -RRB-)))))
              (, ,)
              (CC or)
              (NP
                (NP (DT the) (NN translocation))
                (PP (IN of)
                  (NP
                    (NP
                      (NP (JJ nuclear) (NN factor) (IN of) (VBN activated) (NN T) (NNS cells))
                      (PRN (-LRB- -LRB-)
                        (NP (NN NF-AT))
                        (-RRB- -RRB-)))
                    (PRN (-LRB- -LRB-)
                      (NP (CC both)
                        (NP (JJ primary) (JJ CD4+) (NN T) (NNS cells))
                        (CC and)
                        (NP (NN clone) (NN A2b)))
                      (-RRB- -RRB-)))))
              (, ,)
              (CC and)
              (NP
                (NP (DT the) (NN activity))
                (PP (IN of)
                  (NP
                    (NP (NN p59fyn))
                    (PRN (-LRB- -LRB-)
                      (NP (NN A2b))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN activity))
        (PP (IN of)
          (NP (DT the) (JJ CD4-associated) (NN p56lck)))
        (PP (IN after)
          (NP
            (NP (NN CD4) (NN cross-linking))
            (PRN (-LRB- -LRB-)
              (NP (NN A2b))
              (-RRB- -RRB-)))))
      (VP (VBD was)
        (ADVP (RB comparably))
        (VP (VBN increased)
          (PP (IN by)
            (NP (DT all) (CD three) (JJ anti-CD4) (NNS mAbs)))
          (PRN (-LRB- -LRB-)
            (S
              (NP (DT all) (DT the) (NNS data))
              (VP (RB not) (VBN shown)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN binding) (NNS activities))
        (PP (IN of)
          (NP
            (NP (DT the) (NN transcription) (NNS factors))
            (NP
              (NP
                (NP (NN activator) (NN protein-1))
                (PRN (-LRB- -LRB-)
                  (NP (NN AP-1))
                  (-RRB- -RRB-)))
              (CC and)
              (NP (NN NF-κB))))))
      (VP (VBD were)
        (VP (VBN determined)
          (PP (IN in)
            (NP
              (NP (JJ nuclear) (NNS extracts))
              (PP (IN of)
                (NP
                  (NP (NN spleen) (JJ CD4+) (NN T) (NNS cells))
                  (VP (VBN preincubated)
                    (PP (IN with)
                      (NP (JJ anti-CD4) (NNS mAbs)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN activity))
        (PP (IN of)
          (NP (NN AP-1))))
      (VP (VBD was)
        (ADVP
          (ADVP (RB slightly))
          (CC but)
          (ADVP (RB significantly)))
        (VP (VBN decreased)
          (PP (IN by)
            (NP
              (NP (NN pretreatment))
              (PP (IN with)
                (NP (DT all) (CD three) (JJ anti-CD4) (NNS mAbs)))))
          (, ,)
          (PP (TO to)
            (NP
              (NP (DT a) (JJ similar) (NN degree))
              (PRN (-LRB- -LRB-)
                (NP (NNP Fig.) (CD 3))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (ADVP (RB Interestingly))
    (, ,)
    (NP
      (NP (NN preincubation))
      (PP (IN with)
        (NP
          (NP (DT the) (VBG accelerating) (JJ anti-CD4) (NN mAb))
          (, ,)
          (NP (NN RIB5/2))
          (, ,))))
    (VP (VBD induced)
      (NP
        (NP (DT a)
          (ADJP (RB significantly) (JJR higher))
          (NN binding) (NN activity))
        (PP (IN of)
          (NP (NN NF-κB))))
      (SBAR (IN than)
        (SINV (VBD did)
          (NP
            (NP (NN preincubation))
            (PP (IN with)
              (NP
                (NP (DT the)
                  (NP (JJ ameliorating) (NN W3/25))
                  (CC and)
                  (NP (NN OX35)))
                (, ,)
                (SBAR
                  (WHNP (WDT which))
                  (S
                    (ADVP (RB only) (RB moderately))
                    (VP (VBD increased)
                      (NP (DT the) (JJ NF-κB) (NN binding) (NN activity))
                      (PRN (-LRB- -LRB-)
                        (S
                          (VP (VB see)
                            (NP (NNP Fig.) (CD 3))))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (NP (NN Discussion))))

(
  (S
    (S
      (NP (DT The) (JJ present) (NN study))
      (VP (VBZ shows)
        (NP
          (NP (JJ differential) (JJ clinical) (NN efficacy))
          (PP (IN of)
            (NP (CD three) (JJ anti-CD4) (NNS mAbs)))
          (PP (IN in)
            (NP
              (NP (DT the) (JJ preventive) (NN treatment))
              (PP (IN of)
                (NP (NN AA))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN lack))
        (PP (IN of)
          (NP
            (NP (JJ differential) (JJ clinical) (NN efficacy))
            (PP (IN of)
              (NP (DT the) (JJ same) (NNS mAbs)))
            (PP (IN in)
              (NP (JJ established) (NNS AA))))))
      (VP (MD may)
        (VP (VB be)
          (VP (VBN explained)
            (PP (IN by)
              (NP
                (NP (DT a)
                  (ADJP (RB completely) (JJ divergent))
                  (JJ immunological) (NN constellation))
                (PP (IN in)
                  (NP
                    (NP (NN connection))
                    (PP (IN with)
                      (NP
                        (NP (DT the) (JJ known) (JJ differential) (NNS effects))
                        (PP (IN of)
                          (NP (JJ anti-CD4) (NNS mAbs)))
                        (PP (IN on)
                          (NP
                            (NP
                              (ADJP (JJ naive)))
                            (CC and)
                            (NP (NN memory))
                            (NP (NN T) (NNS cells))))))))))))))
    (. .)))

(
  (S
    (SBAR (IN Although)
      (S
        (NP
          (NP (JJ successful) (NN treatment))
          (PP (IN with)
            (NP (JJ anti-CD4) (NNS mAbs))))
        (VP (VBZ has)
          (VP (VBN been)
            (VP (VBN achieved)
              (PP (IN in)
                (NP (JJ various) (NN arthritis) (NNS models))))))
        (LST (CD -LSB-12,16-18) (-RRB- -RSB-))))
    (, ,)
    (NP (EX there))
    (VP (VBZ is)
      (NP
        (NP (DT no) (NN evidence))
        (PP (IN for)
          (NP
            (NP (DT a) (JJ differential) (NN efficacy))
            (PP (IN of)
              (NP (JJ anti-CD4) (NNS mAbs)))
            (PP (IN in)
              (NP
                (NP (NN arthritis) (NNS models))
                (PP (TO to)
                  (NP (NN date)))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Thus))
      (, ,)
      (NP (DT this) (NN finding))
      (VP (MD may)
        (VP (VB represent)
          (NP
            (NP (DT the) (JJ experimental) (NN counterpart))
            (PP (IN of)
              (NP
                (NP (DT the) (VBG conflicting) (NNS results))
                (VP (VBN observed)
                  (ADVP (RB thus) (RB far))
                  (PP (IN in)
                    (NP
                      (NP (NNS studies))
                      (PP (IN of)
                        (NP (JJ human) (JJ rheumatoid) (NN arthritis) (CD -LSB-6,8,10)))))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN In) (NN contrast) (TO to)
        (NP
          (NP (DT a) (VBN reported) (NN study))
          (PP (IN of)
            (NP
              (NP (JJ experimental) (JJ allergic) (NN encephalomyelitis))
              (CD -LSB-19) (-RRB- -RSB-)))))
      (, ,)
      (NP (DT the) (JJ present) (NN study))
      (VP (VBD did) (RB not)
        (VP (VB confirm)
          (NP
            (NP (DT a) (NN role))
            (PP (IN for)
              (NP (DT the) (NN mAb) (NN isotype)))
            (PP (IN in)
              (NP (NN AA)))))
        (, ,)
        (SBAR (IN as)
          (S
            (NP
              (NP (DT the) (NNS isotypes))
              (PP (IN of)
                (NP (DT the) (CD three) (JJ anti-CD4) (NNS mAbs))))
            (VP (VBD did) (RB not)
              (VP (VBP match)
                (NP
                  (NP (PRP$ their) (JJ differential) (JJ preventive) (NNS effects))
                  (PP (IN in)
                    (NP (NN AA))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ ameliorating) (NN mAb) (NN W3/25))
      (VP (VBD had)
        (NP (DT a)
          (ADJP (RB very) (JJ high))
          (NN affinity))
        (, ,)
        (SBAR (IN as)
          (S
            (ADVP (RB previously))
            (VP (VBN reported)
              (NP (CD -LSB-20) (-RRB- -RSB-))
              (, ,)
              (SBAR (IN whereas)
                (S
                  (NP
                    (NP (DT the) (NN affinity))
                    (PP (IN of)
                      (NP
                        (NP (DT the) (JJ other) (JJ ameliorating) (NN mAb))
                        (, ,)
                        (NP (NN OX35))
                        (, ,))))
                  (VP (VBD was)
                    (ADJP (JJ comparable)
                      (PP (TO to)
                        (NP
                          (NP (DT that))
                          (PP (IN of)
                            (NP
                              (NP (DT the) (VBG accelerating) (NN mAb))
                              (, ,)
                              (NP (NN RIB5/2)))))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN On)
        (NP (DT the) (JJ other) (NN hand)))
      (, ,)
      (NP
        (NP (DT a) (NN contribution))
        (PP (IN of)
          (NP
            (NP (DT the)
              (ADJP (RB strikingly) (JJR higher))
              (NN kdiss))
            (PP (IN of)
              (NP (DT the) (NN mAb) (NN RIB5/2)))))
        (PP (TO to)
          (NP (PRP$ its) (JJ differential) (JJ clinical) (NNS effects))))
      (VP (MD cannot)
        (VP (VB be)
          (VP (VBN excluded)))
        (, ,)
        (PP (IN in) (NN analogy) (TO to)
          (NP
            (NP
              (ADJP
                (ADJP (JJ high))
                (CC and)
                (ADJP (JJ low)))
              (NN kdiss))
            (PP (IN for)
              (NP
                (NP
                  (ADJP
                    (ADJP (JJ agonistic))
                    (CC and)
                    (ADJP (JJ antagonistic)))
                  (NNS TCR-peptides))
                (, ,)
                (ADVP (RB respectively))
                (NP (CD -LSB-21) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (NN spite))
          (PP (IN of)
            (NP (DT these) (NNS considerations)))))
      (, ,)
      (NP
        (NP (NN recognition))
        (PP (IN of)
          (NP (JJ different) (NNS epitopes)))
        (PP (IN by)
          (NP (DT the) (NNS mAbs)
            (NP
              (NP (CD -LSB-14) (-RRB- -RSB-))
              (, ,)
              (PP (IN with)
                (NP
                  (NP (JJ distinct) (JJ functional) (NNS consequences))
                  (PP (IN for)
                    (NP (DT the) (NN target) (NNS cells)))))
              (, ,)))))
      (VP (VBZ remains)
        (NP
          (NP (DT the)
            (ADJP (RBS most) (JJ likely))
            (NN explanation))
          (PP (IN for)
            (NP (PRP$ their) (JJ differential) (JJ clinical) (NN efficacy) (CD -LSB-22)))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (SBAR (IN While)
      (S
        (NP
          (NP (DT the) (VBG binding) (NNS sites))
          (PP (IN of)
            (NP
              (NP (NN W3/25))
              (CC and)
              (NP (NN OX35)))))
        (VP (VBP are)
          (ADJP (JJ situated)
            (PP (IN in)
              (NP
                (NP
                  (NP (DT the) (NN C´–C´´) (NN region))
                  (PP (IN of)
                    (NP (NN domain) (NN D1))))
                (CC and)
                (NP
                  (NP (DT the) (NN B–C) (NN region))
                  (PP (IN of)
                    (NP
                      (NP
                        (NP (NN domain) (NN D2))
                        (PP (IN of)
                          (NP (DT the) (NN CD4) (NN molecule))))
                      (, ,)
                      (ADVP (RB respectively))
                      (NP (NN -LSB-23)))))))))
        (-RRB- -RSB-)))
    (, ,)
    (NP (PRP we))
    (VP (MD could)
      (ADVP (RB roughly))
      (VP (VB localize)
        (NP
          (NP (DT the) (NN epitope))
          (PP (IN of)
            (NP (NN RIB5/2))))
        (PP (IN in)
          (NP
            (NP (DT the) (NN F–G) (NN region))
            (PP (IN of)
              (NP (NN domain) (NN D1)))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN demonstrated)
              (PP (IN by)
                (NP
                  (NP (JJ effective) (NN competition))
                  (PP (IN with)
                    (NP
                      (NP (DT the) (NN mAb) (NN OX65))
                      (PRN (-LRB- -LRB-)
                        (S
                          (NP (NNS data))
                          (VP (RB not) (VBN shown)))
                        (-RRB- -RRB-))))
                  (, ,)
                  (VP (VBN known)
                    (S
                      (VP (TO to)
                        (VP (VB bind)
                          (NP
                            (NP (DT this) (NN region))
                            (PP (IN of)
                              (NP (DT the) (NN CD4) (NN molecule) (CD -LSB-23) (-RRB- -RSB-)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Binding))
        (PP (IN of)
          (NP (JJ anti-CD4) (NNS mAbs)))
        (PP (TO to)
          (NP
            (NP (JJ separate) (NNS epitopes))
            (PP (IN of)
              (NP (DT the) (NN CD4) (NN molecule))))))
      (VP (MD could)
        (VP (VB result)
          (PP (IN in)
            (NP
              (NP (JJ differential) (NNS effects))
              (PP (IN on)
                (NP (NN T-cell) (NNS functions)))))
          (PP (IN by)
            (S
              (VP (VBG inducing)
                (NP
                  (NP
                    (NP (JJ distinct) (JJ conformational) (NNS changes))
                    (PP (IN of)
                      (NP (DT the) (JJ extracellular))))
                  (CC and)
                  (NP
                    (NP (DT the) (JJ intracellular) (NNS parts))
                    (PP (IN of)
                      (NP (DT the) (NN CD4))))))))
          (, ,)
          (S
            (VP (VBG resulting)
              (PP (IN in)
                (NP
                  (NP (VBN modified) (NN interaction))
                  (PP (IN with)
                    (NP (JJ other) (VBG signaling) (NNS molecules))))))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBZ has)
              (VP (VBN been)
                (VP (VBN discussed)
                  (ADVP (RB recently))
                  (PP (IN with)
                    (NP
                      (NP (NN regard))
                      (PP (TO to)
                        (NP (DT the) (NN aspartate) (NN receptor) (CD -LSB-24) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT the) (JJ present) (NN study)))
    (, ,)
    (NP
      (NP (DT the) (JJ ameliorating) (JJ anti-CD4) (NNS mAbs))
      (NP
        (NP
          (NP (NN W3/25))
          (CC and)
          (NP (NN OX35)))
        (PRN (-LRB- -LRB-)
          (CONJP (CC but)
            (RB not))
          (NP
            (NP (DT the) (VBG accelerating) (NN mAb))
            (, ,)
            (NP (NN RIB5/2)))
          (-RRB- -RRB-))))
    (ADVP (RB numerically/significantly))
    (VP (VBD increased)
      (NP
        (NP (DT the) (NN DTH))
        (PP (TO to)
          (NP (DT the) (NN arthritogen) (NN M.) (NN tuberculosis)))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ total) (NN T-cell) (NN population)))
      (, ,)
      (NP
        (NP (CD two))
        (PP (IN of)
          (NP
            (NP (DT the) (CD three) (JJ anti-CD4) (NNS mAbs))
            (-LRB- -LRB-)
            (PP (CC and)
              (PP (IN in)
                (NP (VBN purified) (JJ CD4+) (NN T) (NNS cells)))
              (, ,)
              (NP (DT all) (CD three) (JJ anti-CD4) (NNS mAbs)))
            (-RRB- -RRB-))))
      (VP (VBD increased)
        (NP
          (NP (DT the)
            (ADJP (FW in) (FW vitro))
            (NN reactivity))
          (PP (TO to)
            (NP (NN ConA))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (DT the) (NN case))
          (PP (IN of)
            (NP (JJ CD4+) (NN T) (NNS cells)))))
      (, ,)
      (NP (DT this) (VBN increased) (NN reactivity))
      (VP (VBD was)
        (ADVP (RB negatively))
        (VP (VBN correlated)
          (PP (IN with)
            (NP
              (NP (DT the) (JJ clinical) (NN score))
              (PP (IN of)
                (NP (JJ individual) (NNS animals))))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (JJ successful) (NN mode))
      (PP (IN of)
        (NP
          (NP (NN action))
          (PP (IN of)
            (NP (JJ anti-CD4) (NNS mAbs)))
          (PP (IN in)
            (NP (NNS arthritides))))))
    (VP (MD may)
      (ADVP (RB therefore))
      (VP (VB be)
        (VP (VBN based)
          (PP (IN on)
            (S
              (VP (VBG increasing)
                (NP
                  (NP
                    (NP (DT the) (NN reactivity))
                    (PP (IN of)
                      (NP
                        (NP (DT a) (NN subpopulation))
                        (PP (IN of)
                          (NP (JJ regulatory) (NN T) (NNS cells))))))
                  (, ,)
                  (NP
                    (NP (DT an) (NN interpretation))
                    (SBAR
                      (WHNP (WDT that))
                      (S
                        (VP (VBZ is)
                          (VP (VBN supported)
                            (PP (IN by)
                              (NP
                                (NP
                                  (LST (LS i) (-RRB- -RRB-))
                                  (NP (DT the) (NN increase))
                                  (PP (IN of)
                                    (NP (NN T-cell) (NN reactivity)))
                                  (PP (IN in)
                                    (NP
                                      (NP (DT some) (NNS patients))
                                      (VP
                                        (ADVP (RB successfully))
                                        (VBN treated)
                                        (PP (IN with)
                                          (NP (JJ anti-CD4) (NNS mAbs)))
                                        (PRN
                                          (NP (NN -LSB-6))
                                          (-RRB- -RSB-) (, ,)
                                          (NP
                                            (LST (LS ii) (-RRB- -RRB-))
                                            (NP (DT an) (VBN increased) (NN DTH))
                                            (PP (TO to)
                                              (NP
                                                (NP (NNS antigens))
                                                (PP (IN like)
                                                  (NP
                                                    (NP (NN tetanus) (NN toxoid))
                                                    (PP (IN in)
                                                      (NP
                                                        (ADJP
                                                          (ADJP (RBR less) (JJ active))
                                                          (CC versus)
                                                          (ADJP (JJ active)))
                                                        (JJ rheumatoid) (NN arthritis) (CD -LSB-25))))))))
                                          (-RRB- -RSB-))))))
                                (, ,)
                                (NP
                                  (NP
                                    (LST (LS iii) (-RRB- -RRB-))
                                    (NP (DT the) (VBN reduced) (NN responsiveness))
                                    (PP (TO to)
                                      (NP
                                        (NP (JJ poly-specific) (NN stimulation))
                                        (PP (IN of)
                                          (NP
                                            (NP (NN spleen) (NNS cells))
                                            (PP (IN from)
                                              (NP
                                                (NP (NNS rats))
                                                (PP (IN with)
                                                  (NP (JJ acute) (NNS AA)))))))))
                                    (PP (IN in)
                                      (NP
                                        (NP (NN comparison))
                                        (PP (IN with)
                                          (NP (JJ healthy) (NNS animals))))))
                                  (CD -LSB-26) (-RRB- -RSB-))
                                (, ,)
                                (CC and)
                                (NP
                                  (LST (LS iv) (-RRB- -RRB-))
                                  (NP (DT the)
                                    (ADJP (RB almost) (JJ complete))
                                    (NN restoration))
                                  (PP (IN of)
                                    (NP (NN T-cell) (NN responsiveness)))
                                  (PP (IN upon)
                                    (NP
                                      (NP (NN disease) (NN resolution/transition))
                                      (PP (IN into)
                                        (NP (DT the) (JJ chronic) (NN phase) (NN -LSB-27))))))
                                (-RRB- -RSB-)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (VBG accelerating) (NN mAb) (NN RIB5/2))
      (ADVP (RB significantly))
      (VP (VBD increased)
        (NP
          (NP (DT the) (NN secretion))
          (PP (IN of)
            (NP (NN TNF-α))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN observed)
              (PP (IN in)
                (NP (JJ primary) (JJ CD4+) (NN T) (NNS cells)))
              (PP (CC both)
                (PP (IN upon)
                  (NP (JJ anti-CD4) (NN preincubation)))
                (CC and)
                (PP (IN upon)
                  (NP (NN CD4) (NN cross-linking)))
                (PP (IN after)
                  (NP
                    (NP (NN stimulation))
                    (PP (IN with)
                      (NP (NN TCR))))))
              (PRN (-LRB- -LRB-)
                (S
                  (VP (VB see)
                    (NP (NNP Fig.) (CD 2))))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP
        (NP (NN view))
        (PP (IN of)
          (NP
            (NP (DT the) (JJ known)
              (ADJP
                (ADJP (JJ local))
                (CC and)
                (ADJP (JJ systemic)))
              (NN importance))
            (PP (IN of)
              (NP (NN TNF-α)))
            (PP (IN in)
              (NP
                (NP (JJ experimental) (NN AA) (NN -LSB-28-30) (-RRB- -RSB-))
                (CC and)
                (NP
                  (NP (JJ human) (JJ rheumatoid) (NN arthritis))
                  (CD -LSB-31) (-RRB- -RSB-))))))))
    (, ,)
    (NP (DT this) (NN effect))
    (VP (MD may)
      (VP (VB contribute)
        (PP (TO to)
          (NP
            (NP (DT the) (NN acceleration))
            (PP (IN of)
              (NP
                (NP (DT the) (NN onset))
                (PP (IN of)
                  (NP (NN AA)))))))
        (PP (IN after)
          (NP
            (NP (NN pretreatment))
            (PP (IN with)
              (NP (DT the) (NN mAb) (NN RIB5/2)))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN finding))
      (VP (MD may)
        (VP (VB be)
          (ADJP (JJ important)
            (PP (IN for)
              (NP
                (NP (DT the) (NN understanding))
                (PP (IN of)
                  (NP
                    (NP (NN pathogenesis))
                    (PP (IN in)
                      (NP (NN arthritis))))))))
          (PP (IN despite)
            (NP
              (NP (JJ predominant) (NN production))
              (PP (IN of)
                (NP (NN TNF-α)))
              (PP (IN by)
                (NP
                  (NP (NNS macrophages/monocytes))
                  (-LRB- -LRB-)
                  (VP (VBN reviewed)
                    (PP (IN in)
                      (NP (NN -LSB-32))))
                  (-RRB- -RSB-) (-RRB- -RRB-)))))
          (, ,)
          (SBAR (IN since)
            (S
              (NP
                (NP (NN TNF-α) (NN production))
                (PP (IN by)
                  (NP (NN T) (NNS cells))))
              (VP (VBZ has)
                (VP (VBN been)
                  (VP (VBN demonstrated)
                    (PP (CC both)
                      (PP (IN in)
                        (NP
                          (NP (DT the) (JJ synovial) (NN membrane))
                          (CD -LSB-33) (-RRB- -RSB-)))
                      (CC and)
                      (PP (IN in)
                        (NP
                          (NP (JJ lymphoid) (NNS organs))
                          (PRN (-LRB- -LRB-)
                            (NP (NNS authors)
                              (NP (JJ own) (JJ unpublished) (NNS observations)))
                            (-RRB- -RRB-)))))))))))))
    (. .)))

(
  (S
    (SBAR (IN Since)
      (S
        (NP (NN TNF-α) (NN production))
        (VP (VBZ is)
          (VP (VBN known)
            (S
              (VP (TO to)
                (VP (VB be)
                  (VP (VBN regulated)
                    (ADVP (RB predominantly))
                    (PP (IN by)
                      (NP (JJ NF-κB) (NN -LSB-34)))
                    (-RRB- -RSB-)))))))))
    (, ,)
    (NP (PRP it))
    (VP (VBD was)
      (S
        (VP (VBG revealing)
          (SBAR (IN that)
            (S
              (NP
                (NP (DT the) (VBG accelerating) (NN mAb))
                (, ,)
                (NP (NN RIB5/2)))
              (, ,)
              (PP (IN besides)
                (S
                  (VP (VBG inducing)
                    (NP (NN TNF-α) (NN secretion)))))
              (, ,)
              (ADVP (RB also))
              (VP
                (ADVP (RB strongly))
                (VBD upregulated)
                (NP (JJ NF-κB) (NN binding) (NN activity))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (VBD was)
        (ADJP (RB especially) (JJ striking))
        (SBAR (IN because)
          (S
            (NP
              (NP (NN binding))
              (PP (IN of)
                (NP
                  (NP
                    (NP (DT another) (JJ major) (NN transcription) (NN factor))
                    (VP (VBN involved)
                      (PP (IN in)
                        (NP (NN T-cell) (NN activation)))))
                  (, ,)
                  (NP (NN AP-1) (CD -LSB-35) (-RRB- -RSB-))
                  (, ,))))
            (VP (VBD was)
              (ADVP (RB even) (RB slightly))
              (VP (VBN downregulated)
                (PP (IN by)
                  (NP (DT the) (JJ anti-CD4) (NNS mAbs)))
                (, ,)
                (PP (IN in)
                  (NP
                    (NP (NN line))
                    (PP (IN with)
                      (NP
                        (NP
                          (ADJP (RB recently) (VBN published))
                          (NNS data))
                        (PRN
                          (PP (IN in)
                            (NP (JJ murine) (NNS cells)))
                          (NP (NN -LSB-36))
                          (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT These) (NNS findings))
        (PP (IN in)
          (NP (PRP$ our) (NN study))))
      (VP (VBP support) (, ,)
        (ADVP (RB again))
        (, ,)
        (NP (DT the) (NN notion)
          (SBAR (IN that)
            (S
              (NP
                (NP (JJ NF-κB-mediated) (NN upregulation))
                (PP (IN of)
                  (NP
                    (NP (JJ TNF-α) (NN secretion))
                    (PRN (-LRB- -LRB-)
                      (CC or)
                      (ADVP (RB vice) (RB versa))
                      (-RRB- -RRB-)))))
              (VP (MD may)
                (VP (VB contribute)
                  (PP (TO to)
                    (NP
                      (NP (DT the) (NN acceleration))
                      (PP (IN of)
                        (NP (NN disease) (NN onset)))
                      (PP (IN in)
                        (NP (NN AA)))))
                  (PP (IN upon)
                    (NP
                      (NP (JJ preventive) (NN treatment))
                      (PP (IN with)
                        (NP (NN RIB5/2))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ differential) (JJ clinical) (NN efficacy))
        (PP (IN of)
          (NP (JJ anti-CD4) (NNS mAbs))))
      (VP
        (VP (VBZ is) (RB not)
          (ADJP (JJ restricted)
            (PP (TO to)
              (NP (NN arthritis)))))
        (CC but)
        (VP (VBZ is)
          (ADVP (RB also))
          (VP (VBN observed)
            (PP (IN in)
              (NP (NN transplantation) (NNS models)))
            (NP (CD -LSB-37))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (ADVP (RB However))
    (, ,)
    (SBAR (IN while)
      (S
        (NP
          (NP (JJ preventive) (NN treatment))
          (PP (IN with)
            (NP (DT the) (JJ anti-CD4) (NN mAb) (NN RIB5/2))))
        (VP (VBZ leads)
          (PP (TO to)
            (NP
              (NP (DT an) (NN acceleration))
              (PP (IN of)
                (NP (NN AA))))))))
    (, ,)
    (NP (PRP it))
    (VP (VBZ is)
      (NP
        (NP (DT a)
          (ADJP (RB very) (JJ effective))
          (JJ anti-CD4) (NN mAb))
        (PP (IN for)
          (NP
            (NP (DT the) (NN induction))
            (PP (IN of)
              (NP (NN tolerance)))
            (PP (IN in)
              (NP (NN transplantation) (NNS models) (CD -LSB-14,37) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (VBZ indicates)
        (SBAR
          (SBAR (IN that)
            (S
              (NP
                (NP (JJ clinical) (NN efficacy))
                (-LRB- -LRB-)
                (CC and)
                (NP (PRP$ its) (NN time) (NN course))
                (-RRB- -RRB-))
              (VP (MD may)
                (VP (VB depend)
                  (PP (IN on)
                    (NP (DT the) (JJ actual) (JJ immunological) (NN constellation)))))))
          (CC and)
          (SBAR (IN that)
            (S
              (NP (DT a) (JJ given) (JJ anti-CD4) (NN mAb))
              (VP (MD may)
                (VP (VB have)
                  (NP (JJ beneficial) (NNS effects))
                  (PP
                    (ADVP (RB only))
                    (IN in)
                    (NP
                      (NP (JJ particular) (NNS pathologies))
                      (CC and/or)
                      (NP
                        (NP (NNS stages))
                        (PP (IN of)
                          (NP (NN disease)))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN From)
        (NP
          (NP (DT the) (NNS results))
          (PP (IN of)
            (NP (DT the) (JJ present) (NN study)))))
      (, ,)
      (NP (PRP it))
      (VP (VBZ is)
        (ADJP (JJ evident)
          (SBAR (IN that)
            (S
              (NP
                (NP
                  (NP (DT the) (JJ individual) (NNS features))
                  (CC and)
                  (NP (NNS effects)))
                (PP (IN of)
                  (NP (DT a) (JJ particular) (JJ anti-CD4) (NN mAb))))
              (VP (VBP have)
                (S
                  (VP (TO to)
                    (VP (VB be)
                      (VP (VBN assessed)
                        (PP (IN before)
                          (NP
                            (NP (NN treatment) (NNS trials))
                            (SBAR (IN in) (NN order)
                              (S
                                (VP (TO to)
                                  (VP (VB predict)
                                    (NP (PRP$ its) (JJ clinical) (NN efficacy))
                                    (ADVP (FW in) (FW vivo))))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (MD may)
        (VP (VB require)
          (NP
            (NP (JJ several)
              (ADJP
                (ADJP (FW in) (FW vivo))
                (, ,)
                (ADJP (FW ex) (FW vivo))
                (, ,)
                (CC or)
                (ADJP (FW in) (FW vitro)))
              (NNS assays))
            (PP (IN of)
              (NP (NN T-cell) (NN function)))
            (SBAR (IN in) (NN order)
              (S
                (VP (TO to)
                  (VP (VB reveal)
                    (NP
                      (NP (JJ subtle) (NNS differences))
                      (PP (IN between)
                        (NP (JJ anti-CD4) (NNS mAbs))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Experimental) (NNS models))
        (PP (JJ such) (IN as)
          (NP
            (NP (JJ transgenic) (NNS mice))
            (VP (VBG expressing)
              (NP
                (NP
                  (ADJP (JJ human)))
                (CONJP (CC but)
                  (RB not))
                (NP (NN mouse))
                (NP (NN CD4)))))))
      (VP (MD may)
        (VP (VB make)
          (NP
            (NP (PRP it))
            (ADJP (JJ possible)
              (S
                (VP (TO to)
                  (VP (VB address)
                    (NP (JJ such) (NNS questions))
                    (PP (IN in)
                      (NP (DT the) (JJ future) (NN -LSB-38)))))
                (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (ADVP (RB Recently))
    (, ,)
    (NP (JJ preclinical) (NN testing))
    (VP (VBZ has)
      (VP (VBN been)
        (VP (VBN exploited)
          (PP (IN in)
            (NP (JJ murine) (JJ CD4-knockout/human) (JJ CD4-transgenic) (-LRB- -LRB-) (JJ huCD4-transgenic) (-RRB- -RRB-) (NNS systems)))
          (S
            (VP (TO to)
              (VP (VB assess)
                (NP
                  (NP (DT the) (JJ immunological) (NNS effects))
                  (PP (IN of)
                    (NP (DT a) (JJ particular) (NN anti-human-CD4) (NN mAb)))
                  (PP (IN in)
                    (NP (JJ various) (NN disease) (NNS models) (CD -LSB-39,40) (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Analogous) (JJ preclinical) (NN testing))
      (VP (MD may)
        (VP (VB prove)
          (ADJP (JJ useful)
            (PP
              (ADVP (RB also))
              (IN for)
              (NP
                (NP (DT the) (NN comparison))
                (PP (IN of)
                  (NP
                    (NP (JJ anti-human-CD4) (NNS mAbs))
                    (VP (VBG targeting)
                      (NP (JJ distinct) (NNS epitopes)))))))))))
    (. .)))

(
  (S
    (NP (JJ Supplementary) (NN material))))

(
  (S
    (S
      (NP
        (NP (JJ Female) (NN Lewis) (NNS rats))
        (PRN (-LRB- -LRB-)
          (NP
            (NP
              (NP (CD 8–16) (NNS weeks))
              (ADJP (JJ old)))
            (: ;)
            (NP (NN body) (NN weight)
              (NP (CD 150–220) (NN g))))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP
            (PP (IN from)
              (NP
                (NP (NNP Charles) (NNP River))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Sulzfeld) (, ,) (NNP Germany))
                  (-RRB- -RRB-))))
            (CC or)
            (PP (IN from)
              (NP
                (NP (DT the) (JJ Medical) (JJ Experimental) (NN Center))
                (PP (IN of)
                  (NP
                    (NP (DT the) (NNP University))
                    (PP (IN of)
                      (NP (NN Leipzig)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Female) (JJ inbred) (NN Wistar–Prob) (NNS rats))
        (PRN (-LRB- -LRB-)
          (ADJP
            (NP (CD 12–16) (NNS weeks))
            (JJ old))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN bred)
          (PP (IN in)
            (NP (DT the) (JJ Medical) (JJ Experimental) (NN Center))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS animals))
      (VP (VBD were)
        (VP (VBN kept)
          (PP (IN under)
            (NP
              (NP (JJ standard) (NNS conditions))
              (, ,)
              (NP
                (NP (CD two))
                (PP (IN per)
                  (NP (NN cage))))))
          (, ,)
          (PP (IN with)
            (NP
              (NP
                (NP (NN food))
                (CC and)
                (NP (NN water))
                (NP (NN ad) (NN libitum)))
              (CC and)
              (NP (DT a)
                (ADJP (CD 12) (CD h/12) (NN h))
                (NN light/dark) (NN cycle)))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (NN mouse) (NN anti-rat-CD4) (NNS mAbs))
      (NP
        (NP (NN W3/25))
        (, ,)
        (NP (NN OX35))
        (, ,)
        (CC and)
        (NP
          (NP (NN RIB5/2))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NN IgG1))
              (, ,)
              (NP (NN IgG2a))
              (, ,)
              (CC and)
              (NP (NN IgG2a))
              (, ,)
              (ADVP (RB respectively)))
            (-RRB- -RRB-)))))
    (VP (VBD were)
      (VP
        (VP (VBN used)
          (PP (IN as)
            (NP (NN ascites) (NN fluid)))
          (PP (IN for)
            (NP
              (ADJP (FW in) (FW vivo))
              (NN treatment))))
        (CC or)
        (VP (VBN purified)
          (PP (IN on)
            (NP
              (NP
                (NP
                  (NP
                    (NP (NN Protein) (NN A–sepharose))
                    (PRN (-LRB- -LRB-)
                      (PP (IN for)
                        (NP
                          (NP (NN OX35))
                          (CC and)
                          (NP (NN RIB5/2))))
                      (-RRB- -RRB-)))
                  (CC or)
                  (NP
                    (NP (NN Protein) (NN G–sepharose))
                    (PRN (-LRB- -LRB-)
                      (PP (IN for)
                        (NP (NN W3/25)))
                      (-RRB- -RRB-))))
                (NNS columns))
              (PRN (-LRB- -LRB-)
                (NP (NNP Pharmacia) (, ,) (NNP Freiburg) (, ,) (NNP Germany))
                (-RRB- -RRB-))))
          (PP (IN for)
            (NP (DT all)
              (ADJP (FW in) (FW vitro))
              (NNS experiments))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ maximal) (NN endo-toxin) (NN content))
        (PP (IN of)
          (NP (DT the) (NNS ascites))))
      (VP (VBD was)
        (NP
          (NP
            (NP (CD 58) (NN IU/ml))
            (PRN (-LRB- -LRB-)
              (NP (NN W3/25))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (CD 17) (NN IU/ml))
            (PRN (-LRB- -LRB-)
              (NP (NN RIB5/2))
              (-RRB- -RRB-)))
          (, ,)
          (CC and)
          (NP
            (NP (CD 5) (NN IU/ml))
            (PRN (-LRB- -LRB-)
              (NP (NN OX35))
              (-RRB- -RRB-))))))
    (: ;)
    (S
      (NP
        (NP (DT the) (JJ final) (NN endotoxin) (NNS concentrations))
        (PP (IN for)
          (NP
            (ADJP (FW in) (FW vitro))
            (NNS experiments))))
      (VP (VBD were)
        (ADJP
          (ADJP (JJR less))
          (PP (IN than)
            (NP (CD 1) (NN IU/ml))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP (NN flow) (NN cytometry)))
    (, ,)
    (NP
      (NP
        (ADJP (RB directly) (JJ FITC-labeled))
        (NN W3/25))
      (CC and)
      (NP
        (NP
          (NP
            (NP (NN OX35))
            (PRN (-LRB- -LRB-)
              (NP
                (NP
                  (NP (NNS gifts))
                  (PP (IN from)
                    (NP (NN P) (NN Kühnlein))))
                (, ,)
                (NP
                  (NP (NNP Institute))
                  (PP (IN of)
                    (NP
                      (NP (NNP Virology) (, ,) (NNP University))
                      (PP (IN of)
                        (NP (NNP Würzburg)))))))
              (-RRB- -RRB-)))
          (, ,)
          (CC and)
          (NP
            (NP (DT the) (NNS mAbs) (NN G4.18))
            (PRN (-LRB- -LRB-)
              (NP (NN anti-CD3))
              (, ,)
              (NP (NNP Pharmingen) (, ,) (NNP Hamburg) (, ,) (NNP Germany))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (NN OX8))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (JJ anti-CD8) (, ,) (NNP Serotec) (, ,) (NNP Oxford))
                (: ;)
                (NP (NNP UK)))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (NN OX81))
            (PRN (-LRB- -LRB-)
              (NP (NN anti-IL4) (, ,) (NNP Pharmingen))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (NN A5-4))
            (PRN (-LRB- -LRB-)
              (NP (JJ anti-IL-10) (, ,) (NNP Pharmingen))
              (-RRB- -RRB-)))
          (, ,)
          (CC and)
          (NP (NN DB-1)))
        (PRN (-LRB- -LRB-)
          (NP (CD anti-IFN-γ))
          (, ,)
          (NP (NNP Serotec))
          (-RRB- -RRB-))))
    (VP (VBD were)
      (VP (VBN used)))
    (. .)))

(
  (S
    (S
      (NP (NNS MAbs)
        (NP
          (NP
            (NP (CD MOPC21))
            (PRN (-LRB- -LRB-)
              (NP (NN IgG1))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (CD UPC10))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN IgG2a))
                (, ,)
                (NP
                  (NP (DT both))
                  (PP (IN from)
                    (NP (NN Sigma))))
                (, ,)
                (NP (NNP Deisenhofen) (, ,) (NNP Germany)))
              (-RRB- -RRB-)))
          (CC and)
          (NP
            (NP
              (NP (NN mouse) (NN anti-glucose-oxidase) (NN FITC/phycoerythrin))
              (PRN (-LRB- -LRB-)
                (NP (NN PE))
                (-RRB- -RRB-)))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN IgG1))
                (, ,)
                (NP (NN IgG2a))
                (, ,)
                (NP (NN Dako))
                (, ,)
                (NP (NNP Hamburg) (NNP Germany)))
              (-RRB- -RRB-)))))
      (VP (VBD served)
        (PP (IN as)
          (NP (JJ isotype-matched) (JJ control) (NNS antibodies)))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ anti-TCRα/β) (NN mAb) (NN R73))
      (VP (VBD was)
        (NP
          (NP (DT a) (NN kind) (NN gift))
          (PP (IN of)
            (NP
              (NP (NN T) (NN Hünig))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN Institute))
                  (PP (IN of)
                    (NP
                      (NP (NNP Virology) (, ,) (NNP University))
                      (PP (IN of)
                        (NP (NNP Würzburg))))))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP
        (NP
          (NP (NN sandwich) (NN ELISA))
          (NN analysis))
        (PP (IN of)
          (NP (NN cytokine) (NNS concentrations)))))
    (, ,)
    (NP (DT the) (VBG following) (NNS antibodies))
    (VP (VBD were)
      (VP (VBN used) (: :)
        (NP
          (NP
            (NP (NN DB-1))
            (PRN (-LRB- -LRB-)
              (NP (NN anti-IFN-γ))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (VBN biotinylated) (NN rabbit) (NN anti-rat) (NN IFN-γ))
            (PRN (-LRB- -LRB-)
              (CC both)
              (NP
                (NP (NNP Biosource))
                (, ,)
                (NP (NNP Ratingen) (, ,) (NNP Germany)))
              (-RRB- -RRB-)))
          (: ;)
          (NP (NN rabbit) (NN anti-rat) (NN IL-2))
          (, ,)
          (NP
            (NP (VBN biotinylated) (NN A38-3))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN anti-IL-2))
                (, ,)
                (CC both)
                (NP (NN Pharmingen)))
              (-RRB- -RRB-)))
          (, ,)
          (NP (NN A5-7))
          (, ,)
          (NP
            (NP (VBN biotinylated) (NN A5-6))
            (PRN (-LRB- -LRB-)
              (NP (DT both) (JJ anti-IL-10) (, ,) (NNP Pharmingen))
              (-RRB- -RRB-)))
          (: ;)
          (NP
            (NP (CD OX81))
            (PRN (-LRB- -LRB-)
              (NP (NN anti-IL-4))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (VBN biotinylated) (NN rabbit) (NN anti-rat) (NN IL-4))
            (PRN (-LRB- -LRB-)
              (NP (NN Biosource))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS mAbs))
      (VP (VBD were)
        (VP
          (VP (VBN bound)
            (PP (TO to)
              (NP (DT a) (NN BIAcore) (NN surface)))
            (PP (IN via)
              (NP (NN goat) (JJ anti-mouse) (NN Ig-Fc))))
          (CC and)
          (VP (VBN incubated)
            (PP (IN with)
              (NP
                (NP (JJ various) (NNS concentrations))
                (PP (IN of)
                  (NP
                    (NP (JJ soluble) (NN rat) (NN CD4))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (DT a) (NN gift))
                        (PP (IN of)
                          (NP
                            (NP
                              (NP (NN N))
                              (NNP Barclay))
                            (, ,)
                            (NP (NNP Oxford) (, ,) (NNP UK)))))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (DT The) (NNS data))
        (VP (VBD were)
          (VP (VBN analyzed)
            (PP (IN in)
              (NP
                (NP (NN accordance))
                (PP (IN with)
                  (NP
                    (NP (DT the) (NN method))
                    (PP (IN of)
                      (NP (NNP Karlsson) (FW et) (NN al.-LSB-S1)))))))))
        (-RRB- -RSB-))
      (, ,)
      (CC and)
      (S
        (NP
          (NP
            (NP (DT the) (NN association) (NN rate) (NN constant))
            (NP (NN kass)))
          (, ,)
          (NP
            (NP (DT the) (NN dissociation) (NN rate) (NN constant))
            (NP (NN kdiss)))
          (, ,)
          (CC and)
          (NP
            (NP (DT the) (NN affinity) (NN constant))
            (NP
              (NP (NN KA))
              (PRN (-LRB- -LRB-)
                (NP (NN kass/kdiss))
                (-RRB- -RRB-)))))
        (VP (VBD were)
          (VP (VBN calculated)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Lewis) (NNS rats))
        (PRN (-LRB- -LRB-)
          (ADJP
            (NP (CD 8–12) (NNS weeks))
            (JJ old))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN given)
          (NP
            (NP (CD 0.5) (NN mg)
              (NP
                (NP (JJ heat-inactivated) (NN M.) (NN tuberculosis))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN Difco))
                    (, ,)
                    (NP (NN Detroit))
                    (, ,)
                    (NP (NN MI))
                    (, ,)
                    (NP (NN USA)))
                  (-RRB- -RRB-))))
            (PP (IN in)
              (NP
                (ADJP (CD 100) (NN μl))
                (NN paraffin) (NN oil))))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NNP Riedel) (FW de) (FW Haën))
              (, ,)
              (NP (NNP Seelze) (, ,) (NNP Germany)))
            (-RRB- -RRB-)))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (VP (VBD was)
              (VP (VBN injected)
                (ADVP (RB intradermally))
                (PP (IN into)
                  (NP
                    (NP (DT the) (NN base))
                    (PP (IN of)
                      (NP (DT the) (NN tail)))))))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP (JJ preventive) (NN treatment)))
    (, ,)
    (NP
      (NP (DT the) (NNS rats))
      (PRN (-LRB- -LRB-)
        (NP
          (NP (NN n) (JJ =) (CD 6))
          (PP (IN in)
            (NP (DT each) (NN group))))
        (-RRB- -RRB-)))
    (VP (VBD received)
      (NP
        (NP
          (NP
            (NP (CD 3) (NN mg))
            (PP (IN of)
              (NP (NN RIB5/2))))
          (, ,)
          (NP
            (NP (CD 3) (NN mg))
            (PP (IN of)
              (NP (NN W3/25))))
          (, ,)
          (CC or)
          (NP (CD 2) (NN mg)))
        (PP (IN of)
          (NP (NN OX35))))
      (ADVP
        (ADVP (RB intraperitoneally))
        (PRN (-LRB- -LRB-)
          (FRAG
            (ADJP (JJ corresponding)
              (PP (TO to)
                (NP
                  (QP (CD 17.1)
                    (CC and)
                    (CD 11.4))
                  (NN mg/kg)))
              (, ,)
              (ADVP (RB respectively))
              (, ,)
              (PP (IN on)
                (NP
                  (NP (DT the) (NN basis))
                  (PP (IN of)
                    (NP (DT a) (NN mean) (NN body) (NN weight))))))
            (PP (IN of)
              (NP (CD 175) (NN g))))
          (-RRB- -RRB-)))
      (PP (IN on)
        (NP
          (NP (NNS days))
          (PP
            (PP
              (NP
                (QP (CD -1) (, ,) (CD 0) (, ,) (CD 3) (, ,)
                  (CC and)
                  (CD 6) (, ,) (FW i.e.) (CD 1))
                (NN day))
              (IN before)
              (NP (NN AA) (NN induction)))
            (, ,)
            (PP (IN on)
              (NP
                (NP (DT the) (NN day))
                (PP (IN of)
                  (NP
                    (NP (NN induction))
                    (PRN (-LRB- -LRB-)
                      (NP (NN day) (CD 0))
                      (-RRB- -RRB-))))))
            (, ,)
            (CC and)
            (ADVP (RB thereafter))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (DT The) (JJR lower) (NN dose))
          (PP (IN of)
            (NP (NN OX35))))
        (PRN (-LRB- -LRB-)
          (NP (CD 2) (NN mg))
          (-RRB- -RRB-)))
      (VP (VBD was)
        (VP (VBN chosen)
          (PP (IN on) (DT the) (NN basis) (IN of)
            (NP
              (NP (JJ previous) (NNS experiments))
              (VP (VBG demonstrating)
                (NP
                  (NP (PRP$ its) (JJ high) (JJ clinical) (NN efficacy))
                  (PP (IN in)
                    (NP (NN AA) (NN -LSB-S2) (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ control) (NN group))
      (VP (VBD received)
        (NP (JJ PBS) (NN -LSB-S3) (-RRB- -RSB-))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP
        (NP (JJ preventive) (NN treatment))
        (PP (IN with)
          (NP
            (NP (DT an) (JJ isotype-matched) (NN mAb))
            (PP (IN from)
              (NP (NN birth))))))
      (VP (VBD had)
        (VP (VBN shown)
          (NP
            (NP (DT no) (NN effect))
            (PP (IN on)
              (NP (NN rat) (NNS AA)))
            (PP (IN in)
              (NP (DT a) (JJ previous) (NN study) (NN -LSB-S3)))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP
        (NP (NN determination))
        (PP (IN of)
          (NP (DT the) (NN arthritis) (NN score)))))
    (, ,)
    (NP (DT each) (NN paw))
    (VP (VBD was)
      (VP (VBN graded)
        (PP (VBG according)
          (PP (TO to)
            (NP
              (NP (DT the) (NN extent))
              (PP (IN of)
                (NP
                  (NP
                    (NP (NN erythema))
                    (CC and)
                    (NP (NN edema)))
                  (PP (IN of)
                    (NP (DT the) (JJ periarticular) (NN tissue))))))))
        (, ,)
        (PP (IN on)
          (NP
            (NP (DT a) (NN scale))
            (PP (IN of)
              (NP
                (NP (NN 0–4))
                (PRN (, ,)
                  (SBAR
                    (WHADVP (WRB where))
                    (FRAG
                      (NP
                        (NP (JJ 0=no) (NN inflammation))
                        (, ,)
                        (NP
                          (NP (JJ 1=unequivocal) (NN inflammation))
                          (PP (IN of)
                            (NP (CD one) (NN paw) (NN joint))))
                        (, ,)
                        (NP
                          (NP (JJ 2=unequivocal) (NN inflammation))
                          (PP (IN of)
                            (NP
                              (NP
                                (QP (IN at) (JJS least) (CD two))
                                (NN paw) (NNS joints))
                              (CC or)
                              (NP
                                (NP (JJ moderate) (NN inflammation))
                                (PP (IN of)
                                  (NP (CD one) (NN paw) (NN joint)))))))
                        (, ,)
                        (NP
                          (NP (NN 3=severe) (NN inflammation))
                          (PP (IN of)
                            (NP
                              (QP (CD one)
                                (CC or)
                                (JJR more))
                              (JJ paw) (NNS joints))))
                        (, ,)
                        (CC and)
                        (NP (NN 4=maximum) (NN inflammation)))
                      (PP (IN of)
                        (NP
                          (QP (CD one)
                            (CC or)
                            (JJR more))
                          (JJ paw) (NNS joints)))
                      (ADJP (JJ -LSB-S4))))
                  (, ,)
                  (NP (NNP S5))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS scores))
      (VP (VBD were)
        (ADVP (RB then))
        (VP (VBN added)
          (S
            (VP (TO to)
              (VP (VB obtain)
                (NP
                  (NP (DT the) (JJ total) (NN score))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (JJ maximal) (JJ possible) (NN score))
                      (PP (IN of)
                        (NP (CD 16)))
                      (PP (IN for)
                        (NP (DT each) (NN animal))))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN For)
        (NP
          (NP
            (NP (NN determination))
            (PP (IN of)
              (NP (NN cell) (NN depletion))))
          (CC and)
          (NP
            (NP (NN modulation))
            (PP (IN of)
              (NP (NN surface) (NNS molecules))))))
      (, ,)
      (NP
        (NP (NN blood) (NNS samples))
        (PRN (-LRB- -LRB-)
          (NP (CD 100) (NN μl))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN taken)
          (PP (IN via)
            (NP (JJ retro-orbital) (NN puncture)))
          (PP (IN on)
            (NP
              (NP (NN day) (CD 8))
              (CC or)
              (NP (NN day) (CD 13))))
          (PP (IN after)
            (NP
              (NP (NN induction))
              (PP (IN of)
                (NP (NN AA))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Whole-blood) (NNS cells))
      (VP (VBD were)
        (VP (VBN stained)
          (PP (IN with)
            (NP
              (NP (JJ saturating) (NNS amounts))
              (PP (IN of)
                (NP
                  (NP
                    (ADJP (RB directly) (JJ FITC-labeled))
                    (NN W3/25))
                  (, ,)
                  (NP (NN OX35))
                  (, ,)
                  (NP (NN G4.18))
                  (, ,)
                  (NP (NN OX8))
                  (, ,)
                  (CC or)
                  (NP (JJ respective) (NN isotype))))))
          (, ,)
          (S
            (VP (VBN followed)
              (PP (IN by)
                (NP (NN erythrocyte) (NN lysis))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (CD Ten) (NN thousand) (NNS events))
        (VP (VBD were)
          (VP (VBN analyzed)
            (S
              (VP (VBG using)
                (NP (DT an) (NN Epics) (NN XL) (NN flow) (NN cytometer))))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NNP Coulter))
                (, ,)
                (NP (NNP Krefeld) (, ,) (NNP Germany)))
              (-RRB- -RRB-)))))
      (CC and)
      (S
        (NP (DT the) (NNS results))
        (VP (VBD displayed)
          (PP (IN as)
            (NP (NN histograms))))))
    (. .)))

(
  (S
    (S
      (VP (TO To)
        (VP (VB assess)
          (NP (DT the) (NN DTH)))))
    (, ,)
    (NP
      (NP
        (NP (DT either) (CD 10) (NNS μg))
        (PP (IN of)
          (NP
            (NP (DT the) (JJ arthritogen) (NN M.) (NN tuberculosis))
            (PP (IN in)
              (NP (CD 50) (JJ μl) (NNS PBS))))))
      (, ,)
      (CC or)
      (NP (CD 50) (NN μl) (NNS PBS) (RB only))
      (, ,))
    (VP (VBD were)
      (VP (VBN injected)
        (ADVP (RB intradermally))
        (PP (IN into)
          (NP
            (NP (DT the) (NN pinna))
            (PP (IN of)
              (NP
                (NP (DT the) (JJ left))
                (CC or)
                (NP (DT the) (JJ right) (NN ear))))))
        (, ,)
        (ADVP (RB respectively))
        (, ,)
        (PP (IN on)
          (NP
            (NP (NN day) (CD 13))
            (PP (IN after)
              (NP
                (NP (NN induction))
                (PP (IN of)
                  (NP (NN AA)))))))))
    (. .)))

(
  (S
    (S
      (PP
        (NP (CD One) (NN day))
        (IN after)
        (NP (NN injection)))
      (, ,)
      (NP
        (NP (DT the) (NN swelling))
        (PP (IN of)
          (NP (DT the) (NNS ears))))
      (VP (VBD was)
        (VP (VBN determined)
          (PP (IN with)
            (NP
              (NP (DT a) (NN gauge))
              (PRN (-LRB- -LRB-)
                (NP (NNP Hahn) (NNP &) (NNP Kolb) (, ,) (NNP Stuttgart) (, ,) (NNP Germany))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NN Swelling))
      (VP (VBD was)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP
                (NP (DT the) (NN difference))
                (PRN (-LRB- -LRB-)
                  (NP (NN mm))
                  (-RRB- -RRB-)))
              (PP (IN between)
                (NP
                  (NP (DT the) (NNS thickness))
                  (PP (IN of)
                    (NP (DT the)
                      (ADJP
                        (ADJP (JJ left))
                        (CC and)
                        (ADJP (DT the) (JJ right)))
                      (NN ear))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN T) (NNS cells))
      (VP (VBD were)
        (VP (VBN purified)
          (PP (IN from)
            (NP (NNS spleens)))
          (PP (IN as)
            (NP (VBN described) (NN elsewhere) (CD -LSB-S6)))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (S
        (ADVP (RB Briefly))
        (, ,)
        (NP (DT the) (NNS spleens))
        (VP (VBD were)
          (VP (VBN passed)
            (PP (IN through)
              (NP (DT a) (NN stainless) (NN steel) (NN sieve))))))
      (CC and)
      (S
        (NP (DT the) (VBG resulting) (NN suspension))
        (VP (VBD was)
          (VP (VBN centrifuged)
            (PP (IN through)
              (NP
                (NP (NN Lymphoprep))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Pharmacia))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Cells))
        (VP (VBN contained)
          (PP (IN in)
            (NP (DT the) (NN interphase)))))
      (VP (VBD were)
        (ADVP (RB then))
        (VP
          (VP (VBN washed)
            (ADVP (RB twice)))
          (CC and)
          (VP (VBN loaded)
            (PP (IN onto)
              (NP
                (NP (DT a) (NN 10-ml) (NN syringe))
                (PP (IN with)
                  (NP
                    (NP (CD 1.2) (NN g) (NN nylon) (NN wool))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NNP Polyscience))
                        (, ,)
                        (NP (NNP Eppelheim) (, ,) (NNP Germany)))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (NN incubation))
        (PP (IN for)
          (NP (CD 1) (NN hour)))
        (PP (IN at)
          (NP
            (ADJP
              (QP (CD 37°C) (, ,) (CD 5))
              (NN %))
            (NN CO2)))))
    (, ,)
    (NP (DT the) (NNS cells))
    (VP (VBD were)
      (VP (VBN eluted)
        (PP (IN with)
          (NP
            (NP (NN RPMI) (NN 1640/GlutaMaxI) (NN con-))
            (VP (VBG taining)
              (NP
                (NP
                  (NP
                    (ADJP (CD 10) (NN %))
                    (NN FCS))
                  (, ,)
                  (NP
                    (ADJP (CD 15) (NN mM))
                    (NN HEPES))
                  (, ,)
                  (NP
                    (ADJP (CD 100) (NN U/ml))
                    (NN penicillin))
                  (, ,)
                  (CC and)
                  (NP
                    (ADJP (CD 100) (NN μg/ml))
                    (NN streptomycin)))
                (PRN (-LRB- -LRB-)
                  (ADVP (RB thereafter))
                  (VP (VBN called)
                    (NP
                      (NP (NN R10F))
                      (, ,)
                      (NP
                        (NP (DT all))
                        (PP (IN from)
                          (NP (NNP GIBCO-BRL) (, ,) (NNP Eggenstein) (, ,) (NNP Germany))))))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (VBG resulting) (JJ total) (NN T-cell) (NN suspension))
      (VP (VBD was)
        (ADJP
          (NP (NN ≥) (CD 95) (NN %))
          (JJ CD3+))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN evaluated)
              (PP (IN by)
                (NP (NN flow) (NN cytometry))))))))
    (. .)))

(
  (S
    (S
      (NP (DT Either) (VBN purified) (JJ total) (NN T) (NNS cells))
      (VP (VBD were)
        (ADVP (RB directly))
        (VP (VBN used)
          (PP (IN for)
            (NP (NN proliferation) (NNS assays))))))
    (, ,)
    (CC or)
    (S
      (NP (JJ CD4+) (NN T) (NNS cells))
      (VP (VBD were)
        (ADVP (RB first))
        (ADVP (RB negatively))
        (VP (VBN purified)
          (PP (IN by)
            (S
              (VP
                (VP (VBG adding)
                  (NP
                    (NP (CD 5) (NN μg/1×107) (NNS cells))
                    (VP (VBG OX8)
                      (NP
                        (NP (NN mAb))
                        (PP (IN for)
                          (NP (CD 30) (NN min)))
                        (PP (IN on)
                          (NP (NN ice)))))))
                (CC and)
                (VP (, ,)
                  (PP (IN after)
                    (NP (VBG washing)))
                  (, ,)
                  (NP
                    (NP (CD 75) (NN μl) (NN Dynabeads-M450))
                    (VP (VBN coupled)
                      (PP (TO to)
                        (NP
                          (NP (NN goat) (JJ anti-mouse) (NN IgG))
                          (PRN (-LRB- -LRB-)
                            (NP (NNP Dynal) (, ,) (NNP Hamburg) (, ,) (NNP Germany))
                            (-RRB- -RRB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN suspension))
      (VP (VBD was)
        (ADVP (RB again))
        (VP
          (VP (VBN incubated)
            (PP (IN for)
              (NP (CD 30) (NN min)))
            (PP (IN on)
              (NP (NN ice))))
          (CC and)
          (ADVP (RB then))
          (VP (VBN separated)
            (PP (IN by)
              (NP
                (NP (DT a) (JJ magnetic) (NN particle) (NN concentrator))
                (PRN (-LRB- -LRB-)
                  (NP (NNP MPC®) (, ,) (NNP Dynal))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN purity))
        (PP (IN of)
          (NP (JJ CD4+) (NN T-cell) (NNS populations))))
      (VP (VBD was)
        (ADVP (RB always))
        (NP (NN ≥) (CD 95) (NN %))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN assessed)
              (PP (IN by)
                (NP (NN flow) (NN cytometry))))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP
        (NP (NN enrichment))
        (PP (IN of)
          (NP
            (NP (JJ dendritic) (NNS cells))
            (PRN (-LRB- -LRB-)
              (NP (NN DC))
              (-RRB- -RRB-))))))
    (, ,)
    (NP
      (NP (NNS suspensions))
      (PP (IN of)
        (NP
          (NP (NN spleen) (NNS cells))
          (PP (IN from)
            (NP (JJ healthy) (NNS rats))))))
    (VP (VBD were)
      (VP
        (VP (VBN subjected)
          (PP (TO to)
            (NP (DT an) (JJ overnight) (NN adhesion) (NN step)))
          (PP (IN on)
            (NP
              (NP (NN Petri) (NNS dishes))
              (PRN (-LRB- -LRB-)
                (NP (NNP Falcon®) (, ,) (NNP Becton) (NNP Dickinson) (, ,) (NNP Heidelberg) (, ,) (NNP Germany))
                (-RRB- -RRB-)))))
        (CC and)
        (ADVP (RB then))
        (VP (VBN centrifuged)
          (PP (IN through)
            (NP
              (NP (CD 2) (NN ml))
              (PP (IN of)
                (NP
                  (NP (DT a)
                    (ADJP (CD 14.5) (NN %))
                    (NN metrizamide) (NN solution))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Sigma))
                    (-RRB- -RRB-))))))
          (PP (IN in)
            (NP (NN R10F))))))
    (. .)))

(
  (S
    (S
      (NP (NNS DC))
      (VP (VBD were)
        (ADVP (RB then))
        (ADJP (JJ irradiated)
          (PP (IN with)
            (NP (CD 15) (NN Gy))))
        (S
          (VP (TO to)
            (VP (VB prevent)
              (NP (PRP$ their) (NN proliferation))
              (PP (IN in)
                (NP (JJ subsequent) (NNS assays))))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP (NN proliferation) (NNS assays)))
    (, ,)
    (NP
      (NP
        (QP (CD 1) (NN ×) (CD 105))
        (VBN purified) (NN total))
      (CC or)
      (NP
        (NP (JJ CD4+) (NN spleen) (NN T) (NNS cells))
        (PP (IN per)
          (NP
            (NP (NN well))
            (PP (IN of)
              (NP (JJ 96-well) (NN round-bottom) (NNS plates)))))))
    (VP (VBD were)
      (VP (VBN incubated)
        (PP (IN with)
          (NP
            (NP
              (NP (CD 1) (NN ×) (CD 104) (NN DC))
              (PP (IN per)
                (NP (NN well))))
            (CC and)
            (NP
              (NP (CD 1) (NN μg/ml) (NN ConA))
              (PRN (-LRB- -LRB-)
                (NP (NN Sigma))
                (-RRB- -RRB-)))))
        (PP (IN for)
          (NP (CD 72) (NNS hours)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (ADJP
            (QP (RB Then) (CD 1))
            (NN μCi/well))
          (NN 3H-thymidine))
        (PRN (-LRB- -LRB-)
          (NP (NNP Amersham-Buchler) (, ,) (NNP Braunschweig) (, ,) (NNP Germany))
          (-RRB- -RRB-)))
      (VP (VBD was)
        (VP (VBN added))))
    (. .)))

(
  (S
    (S
      (S
        (PP (IN After)
          (NP
            (NP (DT an) (JJ additional) (NN incubation))
            (PP (IN for)
              (NP (CD 16) (NNS hours)))))
        (, ,)
        (NP (NNS cells))
        (VP (VBD were)
          (VP (VBN harvested)
            (PP (IN onto)
              (NP (NN fiber) (NNS filters))))))
      (CC and)
      (S
        (NP (JJ cell-bound) (NN radioactivity))
        (VP (VBD was)
          (VP (VBN measured)
            (PP (IN by)
              (NP
                (NP (JJ β-scintillation) (NN counting))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Matrix96®) (, ,) (NNP Canberra) (NNP Packard) (, ,) (NNP Dreieich) (, ,) (NNP Germany))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP
            (NP (JJ Total) (NN T) (NNS cells))
            (CC or)
            (NP (VBN purified) (JJ CD4+) (NN T) (NNS cells)))
          (PP (IN from)
            (NP
              (NP (NNS spleens))
              (PP (IN of)
                (NP (JJ healthy) (NN Lewis) (NNS rats))))))
        (, ,)
        (CC and)
        (NP
          (NP (JJ allogeneic) (NNS DC))
          (PP (IN from)
            (NP
              (NP (NNS spleens))
              (PP (IN of)
                (NP (NN Wistar–Prob) (NNS rats))))))
        (, ,))
      (VP (VBD were)
        (VP (VBN prepared)
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (ADVP (RB above))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Total))
        (CC or)
        (NP (JJ CD4+) (NN T) (NNS cells)))
      (VP (VBD were)
        (VP (VBN seeded)
          (PP (IN at)
            (NP
              (NP (CD 4) (NN ×) (CD 105) (NNS cells))
              (PP (IN per)
                (PP (RB well) (IN in)
                  (NP
                    (NP (JJ 96-well) (JJ flat-bottom) (NNS plates))
                    (, ,)
                    (PP
                      (ADVP (RB together))
                      (IN with)
                      (NP
                        (NP
                          (QP (CD 1) (, ,) (CD 2) (, ,)
                            (CC or)
                            (CD 4))
                          (NN ×) (CD 104) (NN DC) (IN per) (RB well))
                        (CC and)
                        (NP
                          (NP
                            (QP (CD 1) (, ,) (CD 5) (, ,)
                              (CC or)
                              (CD 10))
                            (NN μg/ml))
                          (PP (IN of)
                            (NP (DT the) (JJ respective) (VBN purified) (JJ anti-CD4) (NN mAb))))
                        (-LRB- -LRB-)
                        (CC or)
                        (NP (NN isotype) (NN control) (NNS mAbs))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NN incubation))
          (PP (IN for)
            (NP
              (NP (CD 72) (NNS hours))
              (PRN (-LRB- -LRB-)
                (NP (CD 37°C) (, ,) (CD 5) (NN %) (NN CO2))
                (-RRB- -RRB-))))))
      (, ,)
      (S
        (NP
          (NP (NN bromodeoxyuridine))
          (PRN (-LRB- -LRB-)
            (NP (NN BrdU))
            (-RRB- -RRB-)))
        (VP (VBD was)
          (VP (VBN added))))
      (CC and)
      (S
        (NP (NN incubation))
        (VP (VBD was)
          (VP (VBN continued)
            (PP (IN for)
              (NP (DT an) (JJ additional) (CD 16) (NNS hours)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN proliferation))
      (VP (VBD was)
        (VP (VBN determined)
          (PP (IN by)
            (NP (DT a) (NN BrdU) (NN cell-proliferation) (NN ELISA)))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NNP Boehringer) (NNP Mannheim))
              (, ,)
              (NP (NNP Mannheim) (, ,) (NNP Germany)))
            (-RRB- -RRB-))
          (PP (IN in)
            (NP
              (NP (NN accordance))
              (PP (IN with)
                (NP
                  (NP (DT the) (NN supplier) (POS 's))
                  (NNS recommendations))))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP (JJ anti-CD4) (NN preincubation)))
    (, ,)
    (NP (NN spleen) (JJ CD4+) (NN T) (NNS cells))
    (VP (VBD were)
      (VP
        (VP (VBN incubated)
          (PP (IN with)
            (NP
              (NP (DT the)
                (NP (JJ anti-CD4) (NNS mAbs))
                (CC or)
                (NP (NN isotype) (NN control) (NNS mAbs)))
              (PRN (-LRB- -LRB-)
                (NP (CD 10) (NN μg) (IN per) (CD 1) (NN ×) (CD 107) (NNS cells))
                (-RRB- -RRB-))))
          (PP (IN for)
            (NP (CD 30) (NN min)))
          (PP (IN at)
            (NP (NN 4°C))))
        (CC and)
        (VP (VBN washed)
          (ADVP (RB once)))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (VBN bound) (NNS mAbs))
      (VP (VBD were)
        (ADVP (RB then))
        (VP (VBN cross-linked)
          (PP (IN with)
            (NP
              (NP (NN goat) (JJ anti-mouse) (NN IgG))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN Jackson) (NN Lab))
                  (, ,)
                  (NP
                    (QP (CD 20) (CD μg/1) (CD ×) (CD 107))
                    (NNS cells)))
                (-RRB- -RRB-))))
          (PP (IN for)
            (NP
              (NP (CD 1) (NN hour))
              (PP (IN at)
                (NP (NN 37°C))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP (VBG washing)))
      (, ,)
      (NP
        (NP (DT the) (NNS cells))
        (PRN (-LRB- -LRB-)
          (NP
            (QP (CD 1) (CD ×) (CD 106))
            (PP
              (PP (IN per)
                (NP (NN ml)))
              (CC and)
              (PP (IN per)
                (NP (NN well)))))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP
          (VP (VBN seeded)
            (PP (IN in)
              (NP
                (NP (JJ 24-well) (NNS plates))
                (VP
                  (ADVP (RB previously))
                  (VBN coated)
                  (PP (IN with)
                    (NP (NN R73)))))))
          (CC and)
          (VP (VBN harvested)
            (PP (IN after)
              (NP
                (QP (CD 24)
                  (CC and)
                  (CD 48))
                (NNS hours)))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Anti-CD4-preincubated) (NNS cells))
      (VP (VBD were)
        (VP (VBN washed) (, ,)
          (UCP
            (ADJP (JJ fixed)
              (PP (IN with)
                (NP
                  (NP
                    (ADJP (CD 4) (NN %))
                    (NN paraformaldehyde))
                  (PP (IN in)
                    (NP (NNS PBS))))))
            (, ,)
            (ADJP
              (ADJP (JJ permeabilized))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP
                    (NP
                      (ADJP (CD 0.5) (NN %))
                      (NN saponin))
                    (PP (IN in)
                      (NP (NNS PBS))))
                  (, ,)
                  (NP
                    (ADJP (CD 1) (NN %))
                    (NN FCS))
                  (, ,)
                  (NP
                    (ADJP (CD 0.01) (NN %))
                    (NN NaN3)))
                (: ;)
                (S
                  (PP (IN for)
                    (NP (DT this) (NN step)))
                  (, ,)
                  (VP (VBN supplemented)
                    (PP (IN with)
                      (NP
                        (ADJP (CD 10) (NN %))
                        (NN rat) (NN serum)))))
                (-RRB- -RRB-)))
            (, ,)
            (CC and)
            (VP (VBN incubated)
              (PP (IN with)
                (NP
                  (NP
                    (ADJP (CD 1) (NN μg))
                    (NN anti-IFN-γ) (NN FITC))
                  (, ,)
                  (NP (NN anti-IL-4) (NN PE))
                  (, ,)
                  (NP (JJ anti-IL-10) (NN PE))
                  (, ,)
                  (CC or)
                  (NP
                    (ADJP (RB directly) (VBN labeled))
                    (NN isotype-control) (NNS mAbs))))
              (PP (IN for)
                (NP
                  (NP (CD 30) (NN min))
                  (PP (IN at)
                    (NP (NN 4°C))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN FACS) (NN analysis))
      (VP (VBD was)
        (VP (VBN performed)
          (S
            (VP (VBG using)
              (NP
                (NP (DT a) (JJ FACScan®) (NN flow) (NN cytometer))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Becton) (NNP Dickinson))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Detection))
        (PP (IN of)
          (NP (NN TNF-α))))
      (VP (VBD was)
        (VP (VBN performed)
          (S
            (VP (VBG using)
              (NP
                (NP (DT a) (NN bioassay))
                (VP (VBN based)
                  (PP (IN on)
                    (NP
                      (NP (DT the) (NN lysis))
                      (PP (IN of)
                        (NP (DT the) (NN WEHI164/13) (NN cell) (NN line)))
                      (PP (IN after)
                        (NP
                          (NP (NN exposure))
                          (PP (TO to)
                            (NP (NN TNF-α))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Assay) (NN specificity))
      (VP (VBD was)
        (VP (VBN ensured)
          (PP (IN by)
            (S
              (VP (VBG adding)
                (NP (DT a) (NN neutralizing) (NN mAb))
                (PP (TO to)
                  (NP (NN rat) (NN TNF-α) (-LRB- -LRB-) (CD 100) (NN μg/ml) (: ;) (NN clone) (NN 45418.111)))))))))
    (: ;)))

(
  (S
    (S
      (NP (NN R&D) (NNS Systems))
      (, ,)
      (NP (NNP Wiesbaden) (, ,) (NNP Germany) (-RRB- -RRB-)))
    (. .)))

(
  (S
    (S
      (NP (NN Culture) (NNS supernatants))
      (VP (VBD were)
        (VP (VBN analyzed)
          (PP (IN for)
            (NP
              (NP (NN IFN-γ))
              (, ,)
              (NP (NN IL-2))
              (, ,)
              (NP (NN IL-4))
              (, ,)
              (CC and)
              (NP (NN IL-10))))
          (PP (IN by)
            (NP
              (NP (NN sandwich) (NN ELISA))
              (PP (IN with)
                (NP (DT the) (JJ above-mentioned) (NN capture)
                  (CC and)
                  (NN detection) (NNS antibodies))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Recombinant) (NN cytokine) (NNS standards))
      (VP (VBD were)
        (SBAR (IN as)
          (S
            (VP (VBZ follows))))))
    (: :)
    (S
      (NP
        (NP
          (NP (CD IFN-γ))
          (PRN (-LRB- -LRB-)
            (NP (NN Laboserv))
            (-RRB- -RRB-)))
        (, ,)
        (NP
          (NP
            (NP (NN IL-2))
            (, ,)
            (NP (NN IL-10))
            (, ,)
            (CC and)
            (NP (NN IL-4)))
          (PRN (-LRB- -LRB-)
            (NP (NN Pharmingen))
            (-RRB- -RRB-)))))
    (: ;)
    (S
      (NP
        (NP (NN range))
        (PP (IN for)
          (NP
            (NP (NN IFN-γ))
            (, ,)
            (NP (NN IL-2))
            (, ,)
            (CC and)
            (NP (NN IL-10)))))
      (VP (VBD was)
        (NP (CD 39–5000) (NN pg/ml))))
    (: ;)
    (S
      (NP
        (NP (NN range))
        (PP (IN for)
          (NP (NN IL-4))))
      (VP (VBD was)
        (NP (CD 9.85–1250) (NN pg/ml))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Cytokine) (NNS concentrations))
        (PP (IN in)
          (NP (DT the) (NN culture) (NNS supernatants))))
      (VP (VBD were)
        (VP (VBN calculated)
          (PP (IN from)
            (NP
              (NP (DT a) (JJ standard) (NN curve))
              (VP (VBG using)
                (NP
                  (NP (DT the) (NN software) (NN EasyFit))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN SLT))
                      (, ,)
                      (NP (NN Crailsheim))
                      (, ,)
                      (NP (NNP Germany)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (VBN Purified) (NN spleen) (JJ CD4+) (NN T) (NNS cells))
      (VP (VBD were)
        (VP
          (VP (VBN preincubated)
            (PP (IN with)
              (NP (DT the) (JJ anti-CD4) (NNS mAbs)))
            (PP (IN as)
              (NP (JJ above))))
          (CC and)
          (RB then)
          (ADVP (RB either))
          (VP (VBN stimulated)
            (PP
              (PP (IN on)
                (NP
                  (NP (JJ anti-CD3) (JJ mAb-precoated) (JJ 6-well) (NNS plates))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (CD 1) (NN ×) (CD 107) (NNS cells))
                      (PP (IN per)
                        (NP (NN well))))
                    (-RRB- -RRB-))))
              (CC or)
              (PP (IN with)
                (NP
                  (NP (DT a) (NN combination))
                  (PP (IN of)
                    (NP
                      (NP
                        (NP (NN phorbol) (NN myristoyl) (NN acetate))
                        (PRN (-LRB- -LRB-)
                          (NP
                            (NP (NN PMA))
                            (: ;)
                            (NP (CD 10) (NN ng/ml)))
                          (-RRB- -RRB-)))
                      (CC and)
                      (NP
                        (NP (NN ionomycin))
                        (PRN (-LRB- -LRB-)
                          (NP (CD 250) (NN ng/ml))
                          (-RRB- -RRB-))))))))
            (PP (IN for)
              (NP
                (NP (CD 4) (NNS hours))
                (PP (IN at)
                  (NP (NN 37°C)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP (NN stimulation)))
      (, ,)
      (NP (DT the) (NNS cells))
      (VP (VBD were)
        (VP
          (VP (VBN washed)
            (ADVP (RB once))
            (PP (IN with)
              (NP (NNS PBS))))
          (CC and)
          (VP (VBN microcentrifuged)
            (PRN (-LRB- -LRB-)
              (NP (CD 10,000) (NN ×) (NN g))
              (-RRB- -RRB-))
            (PP (IN at)
              (NP (NN 4°C)))
            (PP (IN for)
              (NP (CD 1) (NN min)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN pellet))
      (VP (VBD was)
        (VP
          (VP (VBN resuspended)
            (PP (IN in)
              (NP (CD 400) (NN μl) (JJ ice-cold)
                (NP
                  (NP (NN buffer) (NN A))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 10) (NN mM) (NNS HEPES))
                    (, ,)
                    (NP
                      (ADJP (CD 10) (NN mM))
                      (NN KCl))
                    (, ,)
                    (NP
                      (NP
                        (ADJP (CD 0.1) (NN mM))
                        (NN EDTA))
                      (, ,)
                      (NP
                        (ADJP (CD 0.1) (NN mM))
                        (NN EGTA))
                      (, ,)
                      (NP
                        (ADJP (CD 0.5) (NN mM))
                        (NN PMSF))
                      (, ,)
                      (NP
                        (ADJP (CD 1) (NN mM))
                        (NN dithiothreitol))
                      (, ,)
                      (CC and)
                      (NP
                        (ADJP (CD 1) (NN mM))
                        (NN Na3VO4)))
                    (-RRB- -RRB-))))))
          (CC and)
          (VP (VBN placed)
            (PP (IN on)
              (NP (NN ice)))
            (PP (IN for)
              (NP (CD 15) (NN min)))))))
    (. .)))

(
  (S
    (S
      (S
        (ADVP (RB Subsequently))
        (, ,)
        (NP
          (NP (CD 25) (NNS μl))
          (PP (IN of)
            (NP
              (NP (DT a)
                (ADJP (CD 10) (NN %))
                (NP (NN Nonidet) (NN P-40))
                (NN solution))
              (PRN (-LRB- -LRB-)
                (NP (NNP Boehringer) (NNP Mannheim))
                (-RRB- -RRB-)))))
        (VP (VBD were)
          (VP (VBN added)
            (PP (TO to)
              (NP (DT the) (NN sample))))))
      (CC and)
      (S
        (NP (DT the) (NNS cells))
        (VP (VBD were)
          (VP (VBN homogenized)
            (PP (IN by)
              (S
                (VP (VBG vortexing)
                  (PP (IN for)
                    (NP (CD 30) (NN s)))
                  (S
                    (VP (VBN followed)
                      (PP (IN by)
                        (NP
                          (NP (NN microcentrifugation))
                          (PP (IN for)
                            (NP (CD 1) (NN min))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ nuclear) (NNS pellets))
      (VP (VBD were)
        (VP
          (VP (VBN resuspended)
            (PP (IN in)
              (NP
                (NP (CD 50) (NN μl))
                (PP (IN of)
                  (NP
                    (NP (NN buffer) (NN B))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 20) (NN mM) (NNS HEPES))
                      (, ,)
                      (NP
                        (NP
                          (ADJP (CD 400) (NN mM))
                          (NN NaCl))
                        (, ,)
                        (NP
                          (NP
                            (ADJP (CD 0.1) (NN mM))
                            (NN EDTA))
                          (, ,)
                          (NP
                            (ADJP (CD 0.1) (NN mM))
                            (NN EGTA))
                          (, ,)
                          (NP
                            (ADJP (CD 2) (NN mM))
                            (NN PMSF))
                          (, ,)
                          (NP
                            (ADJP (CD 1) (NN mM))
                            (NN dithiothreitol))
                          (, ,)
                          (CC and)
                          (NP
                            (ADJP (CD 1) (NN mM))
                            (NN Na3VO4))))
                      (-RRB- -RRB-)))))))
          (CC and)
          (VP (VBN shaken)
            (PP (IN for)
              (NP
                (NP (CD 15) (NN min))
                (PP (IN at)
                  (NP (NN 4°C)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NN microcentrifugation))
          (PP (IN for)
            (NP
              (NP (CD 5) (NN min))
              (PP (IN at)
                (NP (NN 4°C)))))))
      (, ,)
      (NP (DT the) (NNS supernatants))
      (VP (VBD were)
        (VP
          (VP (VBN aliquoted))
          (CC and)
          (VP (VBN stored)
            (PP (IN at)
              (NP (NN -70°C)))
            (PP (IN until)
              (NP (JJ further) (NN use)))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (JJ nuclear) (NNS extracts))
      (PRN (-LRB- -LRB-)
        (NP (CD 10) (NN μg) (JJ total) (NN protein))
        (-RRB- -RRB-)))
    (VP (VBD were)
      (SBAR (IN than)
        (S
          (VP (VBN incubated)
            (PP (IN with)
              (NP
                (NP (CD 2) (NN ×) (CD 108) (NN cpm))
                (PP (IN of)
                  (NP
                    (NP
                      (NP (JJ 32P-labeled) (, ,) (JJ double-stranded) (NN oligonucleotide) (NN probe))
                      (PRN (-LRB- -LRB-)
                        (NP
                          (NP (NN sense) (NN strand))
                          (ADVP (RB only)))
                        (: ;)
                        (NP
                          (NP
                            (NP
                              (NP (NN AP-1))
                              (: :)
                              (NP
                                (NP (JJ 5'-CGC) (NN TTG) (NN ATG) (NN AGT) (NN CAG) (NN CCG) (NN GAA-3))
                                ('' '))
                              (: ;)
                              (NP (NN NF-κB))
                              (: :)
                              (NP (NN 5'-AGT) (NN TGA) (NN GGG)))
                            (JJ GAC) (NN TTT) (NN CCC) (NN AGG) (NN C-3) (POS '))
                          (: ;)
                          (NP
                            (NP (DT both))
                            (PP (IN from)
                              (NP (NNP Promega) (, ,) (NNP Mannheim) (, ,) (NNP Germany))))
                          (: ;)
                          (NP (NN NF-AT))
                          (: :)
                          (NP (JJ 5'-CGC) (NN CCA) (NN AAG) (NN AGG) (NN AAA) (NN ATT) (NN TGT) (NN TTC) (NN ATA-3) (POS '))
                          (: ;)
                          (NP (NNP Santa) (NNP Cruz) (, ,) (NNP Heidelberg) (, ,) (NNP Germany)))
                        (-RRB- -RRB-)))
                    (PP (IN in)
                      (NP
                        (NP
                          (ADJP (CD 25) (NN μl))
                          (NN binding) (NN buffer))
                        (PRN (-LRB- -LRB-)
                          (FRAG
                            (NP
                              (ADJP (CD 1) (NN M))
                              (NN Tris))
                            (, ,)
                            (NP
                              (ADJP (CD 1) (NN M))
                              (JJ boric) (NN acid))
                            (, ,)
                            (NP
                              (ADJP (CD 0.02) (NN M))
                              (NN EDTA))
                            (, ,)
                            (NP
                              (ADJP (CD 5) (NN %))
                              (NN glycerol)))
                          (-RRB- -RRB-))))))
                (VP (VBN supplemented)
                  (PP (IN with)
                    (NP
                      (NP
                        (NP (NN poly) (NN -LSB-dI-dC) (-RRB- -RSB-))
                        (PRN (-LRB- -LRB-)
                          (NP (CD 0.16) (NN mg/ml)
                            (NP (NNP Pharmacia)))
                          (-RRB- -RRB-)))
                      (CC and)
                      (NP
                        (ADJP (CD 2) (NN mM))
                        (NN dithiothreitol)))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS samples))
      (VP (VBD were)
        (VP (VBN separated)
          (PP (IN on)
            (NP (DT a)
              (ADJP (CD 4) (NN %))
              (NN polyacrylamide) (NN gel)))
          (PP (IN at)
            (NP (CD 200) (NN V))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NN scanning))
          (PP (IN in)
            (NP
              (NP (DT a) (NN phosphor) (NN imager))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (CD BAS-1000))
                  (, ,)
                  (NP
                    (NP
                      (NP (NNP Fuij))
                      (NP (NN Photo) (NN Film) (NN Co.)))
                    (NP (NNP Ltd) (, ,) (NNP Japan))))
                (-RRB- -RRB-))))))
      (, ,)
      (NP (DT the) (NNS bands))
      (VP (VBD were)
        (VP (VBN quantified)
          (S
            (VP (VBG using)
              (NP (DT the) (NN PCBAS) (NN 2.09g) (NN software))))
          (PRN (-LRB- -LRB-)
            (NP
              (NP
                (NP (NNP Fuij))
                (NP (NN Photo) (NN Film) (NN Co.)))
              (NP (NNP Ltd)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Differences))
        (PP (IN between)
          (NP (JJ experimental) (NNS groups))))
      (VP (VBD were)
        (VP (VBN evaluated)
          (PP (IN with)
            (NP (DT the) (JJ two-tailed) (JJ nonparametric) (NN Mann–Whitney) (-LRB- -LRB-) (NN U) (-RRB- -RRB-) (NN test))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ Spearman) (NN rank) (NN correlation) (NN test))
      (VP (VBD was)
        (VP (VBN used)
          (S
            (VP (TO to)
              (VP (VB verify)
                (SBAR (IN whether)
                  (S
                    (NP
                      (NP (DT the) (FW ex) (NN vivo  3H-thymidine) (NN uptake))
                      (PP (IN of)
                        (NP (JJ CD4+) (NN T) (NNS cells))))
                    (VP (VBD correlated)
                      (PP (IN with)
                        (NP
                          (NP (DT the) (NN arthritis) (NN score))
                          (PP (IN of)
                            (NP (JJ individual) (NNS rats))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Statistical) (NN significance))
      (VP (VBD was)
        (VP (VBN accepted)
          (PP (IN at)
            (NP
              (NP (NN P))
              (CC ≤)
              (NP (CD 0.05)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (JJ Total) (NN T) (NNS cells))
          (CC and)
          (NP (JJ CD4+) (NN T) (NNS cells)))
        (PP (IN from)
          (NP
            (NP (NNS spleens))
            (PP (IN of)
              (NP
                (NP (JJ individual) (NNS rats))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN day) (CD 13))
                    (PP (IN of)
                      (NP (NNS AA))))
                  (-RRB- -RRB-)))))))
      (VP (VBD were)
        (VP (VBN stimulated)
          (ADVP (FW in) (FW vitro))
          (PP (IN with)
            (NP (NN ConA))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The)
          (ADJP (FW in) (FW vitro))
          (NN proliferation) (NNS rates))
        (PP (IN of)
          (NP
            (NP (JJ total) (NN T) (NNS cells))
            (PP (IN from)
              (NP
                (ADJP
                  (ADJP (JJ OX35-))
                  (CC and)
                  (ADJP (JJ W3/25-treated)))
                (NNS animals)))))
        (PP (IN in)
          (NP
            (NP (NN response))
            (PP (TO to)
              (NP
                (NP (JJ polyspecific) (NN stimulation))
                (PP (IN with)
                  (NP (NN ConA))))))))
      (VP (VBD were)
        (ADJP
          (ADJP (JJR higher))
          (PP (IN than)
            (NP
              (NP (DT those))
              (PP (IN of)
                (NP (JJ PBS-treated) (NNS rats))))))
        (, ,)
        (SBAR (IN while)
          (S
            (NP
              (NP (NN T) (NNS cells))
              (PP (IN of)
                (NP (DT the) (JJ RIB5/2-treated) (NNS rats))))
            (VP (VBD showed)
              (NP
                (NP (NN proliferation) (NNS rates))
                (ADJP (JJ similar)
                  (PP (TO to)
                    (NP
                      (NP (DT those))
                      (PP (IN of)
                        (NP
                          (NP (NN T) (NNS cells))
                          (PP (IN from)
                            (NP
                              (NP (JJ PBS-treated) (NNS animals))
                              (PRN (-LRB- -LRB-)
                                (NP
                                  (NP (NN Supplementary))
                                  (NP (NNP Fig.) (CD 2)))
                                (-RRB- -RRB-)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN ConA) (NN stimulation))
        (PP (IN of)
          (NP (JJ CD4+) (NN T) (NNS cells))))
      (VP (VBD resulted)
        (PP (IN in)
          (NP
            (NP
              (ADJP (RB generally) (JJR lower))
              (NN proliferation) (NNS rates))
            (PP (IN than)
              (NP
                (NP (DT those))
                (PP (IN of)
                  (NP
                    (NP (JJ total) (NN T) (NNS cells))
                    (PP (IN in)
                      (NP (JJ PBS-treated) (NNS rats)))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP
        (NP (DT the) (NNS values))
        (PP (IN of)
          (NP
            (NP (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP (JJ individual) (, ,) (JJ anti-CD4-treated) (NNS animals))))))
      (VP (VBD were)
        (ADJP
          (ADJP (RB always) (JJR higher))
          (PP (IN than)
            (NP
              (NP (DT those))
              (PP (IN of)
                (NP
                  (NP (DT the) (JJ PBS-treated) (NN control) (NN group))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Supplementary) (NNP Fig.) (NN 3a))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (EX There))
      (VP (VBD was)
        (NP
          (NP (DT a)
            (ADJP (RB highly) (JJ significant))
            (JJ negative) (NN correlation))
          (PP (IN between)
            (NP
              (NP
                (NP (DT the) (NN degree))
                (PP (IN of)
                  (NP
                    (NP (DT the) (JJ ConA-induced) (NN proliferation))
                    (PP (IN of)
                      (NP (JJ CD4+) (NN spleen) (NN T) (NNS cells))))))
              (CC and)
              (NP
                (NP (DT the) (NN severity))
                (PP (IN of)
                  (NP (DT the) (NN arthritis) (NN score))))))
          (, ,)
          (PP (FW i.e.)
            (NP
              (NP (DT the) (JJR lower)
                (NP (DT the) (NN arthritis) (NN score)))
              (, ,)
              (NP (DT the) (JJR higher)
                (NP
                  (NP (DT the) (NN proliferation) (NN rate))
                  (PRN (-LRB- -LRB-)
                    (NP (JJ Supplementary) (NNP Fig.) (NN 3b))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT these) (NNS experiments)))
      (, ,)
      (NP
        (NP (DT the) (JJ inhibitory) (NN potency))
        (PP (IN of)
          (NP (DT the) (JJ anti-CD4) (NNS mAbs)))
        (PP (IN on)
          (NP
            (NP (DT the) (JJ mixed) (NN lymphocyte) (NN culture))
            (, ,)
            (NP
              (NP (DT an) (NN equivalent))
              (PP (IN of)
                (NP (DT a) (NN transplant) (NN rejection))))
            (, ,))))
      (VP (VBD was)
        (VP (VBN investigated)
          (PP (IN as)
            (NP
              (NP (DT a) (NN model))
              (PP (IN for)
                (NP (JJ MHC-dependent) (NN T-cell) (NN activation))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ anti-CD4) (NNS mAbs))
      (ADVP (RB moderately))
      (VP (VBD inhibited)
        (NP
          (NP (DT the) (NN proliferation))
          (PP (IN of)
            (NP (JJ total) (NN spleen) (NN T) (NNS cells))))
        (, ,)
        (PP (VBG depending)
          (PP (IN on)
            (NP
              (NP (DT the) (NN stimulator) (NN cell) (NN concentration))
              (PRN (-LRB- -LRB-)
                (NP (NN Supplementary) (NNP Fig.) (NN 4a))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (NP (DT The) (VBG accelerating) (NN mAb) (NN RIB5/2))
    (VP (VBD led)
      (PP (TO to)
        (NP
          (NP (JJ significant) (NN inhibition))
          (PP (IN at)
            (NP
              (NP (DT all) (NNS concentrations))
              (PP (IN of)
                (NP
                  (NP
                    (NP (NN mAb))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (QP (CD 1) (, ,) (CD 5) (, ,)
                          (CC and)
                          (CD 10))
                        (NN μg/ml))
                      (: ;)
                      (S
                        (NP
                          (QP (RB only) (CD 1))
                          (NN μg/ml))
                        (VP (VBZ is)
                          (VP (VBN shown)
                            (PP (IN in)
                              (NP (JJ Supplementary) (NNP Fig.) (NN 4a))))))
                      (-RRB- -RRB-)))
                  (CC and)
                  (NP (NN DC))))))))
      (, ,)
      (SBAR (IN whereas)
        (S
          (NP (DT the) (JJ other) (CD two) (JJ anti-CD4) (NNS mAbs))
          (ADVP (RB significantly))
          (VP (VBD inhibited)
            (NP (DT the) (NN proliferation))
            (PP
              (ADVP (RB only))
              (IN in)
              (NP (DT some) (NNS cases)))))))
    (. .)))

(
  (S
    (ADVP (RB Furthermore))
    (, ,)
    (NP (NN RIB5/2))
    (VP (VBD inhibited)
      (NP
        (NP (DT the) (NN proliferation))
        (PP (TO to)
          (NP
            (NP
              (NP (DT a)
                (ADJP (RB statistically) (JJ significant))
                (NN degree))
              (PP (IN at)
                (NP (CD 1) (NN μg/ml))))
            (CC and)
            (NP (CD 2) (NN ×) (NN 104) (NN DC/well)))))
      (ADVP
        (ADVP (RBR more) (RB strongly))
        (PP (IN than)
          (NP (CC both)
            (NP (NN W3/25))
            (CC and)
            (NP (NN OX35))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Thus))
      (, ,)
      (NP (DT these) (JJ differential) (NNS results))
      (PRN (-LRB- -LRB-)
        (ADVP (RB inversely))
        (-RRB- -RRB-))
      (VP (VBP match)
        (NP
          (NP (DT the) (JJ differential) (JJ clinical) (NN efficacy))
          (VP (VBN seen)
            (PP (IN with)
              (NP (DT the) (CD three) (NNS mAbs)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN possibility)
        (SBAR (IN that)
          (S
            (NP (JJ CD8+) (NN T) (NNS cells))
            (VP (MD would)
              (VP (VB mask)
                (NP
                  (NP (DT the) (JJ inhibitory) (NN potency))
                  (PP (IN of)
                    (NP (DT the) (JJ anti-CD4) (NNS mAbs))))
                (PP (IN on)
                  (NP
                    (NP (DT the) (NN proliferation))
                    (PP (IN of)
                      (NP
                        (NP (JJ CD4+) (NN T) (NNS cells))
                        (PP (IN in)
                          (NP (DT a) (JJ total) (NN T-cell) (NN population))))))))))))
      (VP (VBD was)
        (VP (VBN excluded)
          (PP (IN by)
            (S
              (VP (VBG using)
                (NP (VBN purified) (JJ CD4+) (NN T) (NNS cells))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP They))
      (VP (VBD showed)
        (NP
          (NP (DT a) (JJ clearer) (NN inhibition))
          (PP (IN of)
            (NP
              (NP (PRP$ their) (NN proliferation) (NNS rates))
              (PRN (-LRB- -LRB-)
                (NP
                  (QP (CD 50) (TO to) (CD 80))
                  (NN %))
                (PP (IN in)
                  (NP
                    (NP (NN comparison))
                    (PP (IN with)
                      (NP (DT the) (NN isotype)))))
                (-RRB- -RRB-)))))
        (SBAR
          (WHADVP (WRB when))
          (S
            (VP (VBN used)
              (PP (IN as)
                (NP (NN responder) (NNS cells))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (PP (IN in) (NN contrast) (TO to)
        (NP (DT the) (JJ total) (NN T-cell) (NN population)))
      (, ,)
      (NP (EX there))
      (VP (VBD was)
        (NP
          (NP (DT no) (JJ significant) (NN difference))
          (PP (IN in)
            (NP (DT the) (JJ inhibitory) (NN potency)))
          (PP (IN among)
            (NP (DT the) (CD three) (JJ anti-CD4) (NNS mAbs))))
        (PRN (-LRB- -LRB-)
          (NP (JJ Supplementary) (NNP Fig.) (NN 4b))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (SBAR (IN In) (NN order) (TO to)
        (S
          (VP (VB characterize)
            (NP
              (NP (DT the)
                (ADJP
                  (ADJP (VBG depleting))
                  (CC and)
                  (ADJP (VBG modulating)))
                (NN capacity))
              (PP (IN of)
                (NP (DT the) (CD three) (NNS mAbs)))))))
      (, ,)
      (NP
        (NP (NN FACS))
        (PP (IN of)
          (NP (JJ peripheral) (NN blood) (JJ mononu-clear) (NNS cells))))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN on)
            (NP
              (NP (NNS days) (CD 8)
                (CC and)
                (CD 13))
              (PP (IN of)
                (NP
                  (NP (NN AA))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN Supplementary) (NN Table) (NN 2A))
                      (, ,)
                      (NP (NN B)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD Two) (JJ different) (JJ anti-CD4) (NNS mAbs))
        (PRN (-LRB- -LRB-)
          (NP
            (NP
              (NP (CD W3/25))
              (CC and)
              (NP (CD OX35)))
            (, ,)
            (SBAR
              (WHNP (WDT which))
              (S
                (VP (VBP do) (RB not)
                  (VP (VB compete)
                    (PP (IN for)
                      (NP (NN CD4) (NN binding))))))))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN employed)
          (S
            (VP (TO to)
              (VP (VB differentiate)
                (PP (VBG coating)
                  (PP (IN with)
                    (NP (JJ therapeutic) (NN mAb))))
                (PP (IN from)
                  (NP
                    (NP (NN depletion))
                    (PP (IN of)
                      (NP (JJ CD4+) (NN T) (NN cells/CD4-modulation)))))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (NN treatment))
        (PP (IN with)
          (NP (NN W3/25)))))
    (, ,)
    (NP
      (NP
        (NP (DT the) (NN percentage))
        (CC and/or)
        (NP
          (NP (NN MFI))
          (PRN (-LRB- -LRB-)
            (NP (NN mean) (NN fluorescence) (NN intensity))
            (-RRB- -RRB-))))
      (PP (IN of)
        (NP
          (NP (JJ CD3+) (NNS cells))
          (PP (IN in)
            (NP
              (NP (DT the) (JJ peripheral) (NN blood))
              (PP (IN on)
                (NP (NNS days) (CD 8)
                  (CC and)
                  (CD 13))))))))
    (VP (VBD was)
      (ADJP
        (ADJP (RB numerically) (JJR lower))
        (PP (IN than)
          (PP (IN in)
            (NP (DT the) (JJ PBS-treated) (NN control) (NN group)))))
      (, ,)
      (S
        (VP (VBG resulting)
          (PP (IN in)
            (NP
              (NP (DT a)
                (ADJP (RB significantly) (JJR lower))
                (NN MFI))
              (PP (IN on)
                (NP
                  (NP (NN day) (CD 13))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN note))
                      (: :)
                      (NP
                        (NP (DT the) (NN fact))
                        (SBAR
                          (WHNP (WDT that))
                          (S
                            (PP (IN on)
                              (NP (NN day) (CD 8)))
                            (NP
                              (NP
                                (QP (RB only) (CD two))
                                (NNS animals))
                              (PP (IN of)
                                (NP (DT the) (JJ W3/25-treated) (NN group))))
                            (VP (VBD were)
                              (VP (VBN investigated)
                                (ADVP (RB likely))
                                (VP (VBN prevented)
                                  (NP (JJ statistical) (NN significance) (-RRB- -RRB-)))))))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Furthermore))
      (, ,)
      (NP
        (NP (DT a) (NN decrease))
        (PP (IN of)
          (NP (JJ CD4+) (NNS cells))))
      (VP (VBD was)
        (VP (VBN observed)
          (SBAR
            (WHADVP (WRB when))
            (S
              (NP (DT the) (NNS cells))
              (VP (VBD were)
                (VP (VBN stained)
                  (PP (IN with)
                    (NP (NN OX35)))
                  (PRN (-LRB- -LRB-)
                    (FRAG
                      (ADJP (RBR more) (JJ prominent))
                      (PP (IN on)
                        (NP (NN day) (CD 13))))
                    (: ;)
                    (S
                      (VP (VB see)
                        (NP (JJ Supplementary) (NN Table) (NN 2B))))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP
          (ADJP (FW ex) (FW vivo))
          (NN staining))
        (PP (IN with)
          (NP (NN W3/25) (NN –)))))
    (NP
      (NP (DT the) (NN mAb))
      (VP
        (ADVP (RB also))
        (VBN used)
        (PP (IN for)
          (NP (NN treatment)))
        (PP (IN –)
          (NP
            (NP
              (NP
                (NP
                  (QP (RB only) (CD 7))
                  (NN %))
                (PRN (-LRB- -LRB-)
                  (NP (NN day) (CD 8))
                  (-RRB- -RRB-)))
              (CC and)
              (NP
                (NP (CD 28) (NN %))
                (PRN (-LRB- -LRB-)
                  (NP (NN day) (CD 13))
                  (-RRB- -RRB-))))
            (PP (IN of)
              (NP (DT the) (JJ peripheral) (NN blood)
                (NP (JJ mononuclear) (NNS cells))))))))
    (VP (VBD were)
      (ADJP (JJ CD4+)))
    (. .)))

(
  (S
    (S
      (S
        (NP (DT This) (NN fact)))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (DT the) (JJ positive) (NN staining))
          (PP (IN with)
            (NP (DT an) (JJ anti-mouse) (NN IgG)))
          (PP (IN on)
            (NP
              (NP (NNS days) (CD 8)
                (CC and)
                (CD 13))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP
                    (NP (CD 18) (NN %))
                    (CC and)
                    (NP (CD 9) (NN %)))
                  (, ,)
                  (ADVP (RB respectively)))
                (-RRB- -RRB-))))
          (, ,))
        (VP (VBD showed)
          (SBAR (IN that)
            (S
              (NP (DT the) (JJ therapeutic) (JJ anti-CD4) (NN mAb))
              (VP (VBD was)
                (ADJP (JJ present)
                  (PP (IN on)
                    (NP
                      (NP (DT the) (NNS cells))
                      (CONJP (RB as) (RB long) (IN as))
                      (NP
                        (NP (CD 7) (NNS days))
                        (PP (IN after)
                          (NP
                            (NP (DT the) (JJ last) (NN injection))
                            (PP (IN of)
                              (NP (DT the) (NN mAb)))))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NN treatment))
          (PP (IN with)
            (NP (NN W3/25)))))
      (, ,)
      (NP
        (NP (DT the) (NN percentage))
        (PP (IN of)
          (NP (JJ CD8+) (NNS cells))))
      (VP (VBD did) (RB not)
        (VP (VB show)
          (NP (DT any) (JJ significant) (NNS changes))
          (PP (IN on)
            (NP (NNS days) (CD 8)
              (CC or)
              (CD 13))))))
    (: ;)
    (S
      (ADVP (RB however))
      (, ,)
      (NP
        (NP (DT the) (NN MFI))
        (PP (IN for)
          (NP (NN CD8)))
        (PP (IN on)
          (NP (NN day) (CD 13))))
      (VP (VBD was)
        (ADVP (RB significantly))
        (VP (VBN decreased)
          (PRN (-LRB- -LRB-)
            (S
              (VP (VB see)
                (NP (JJ Supplementary) (NN Table) (NN 2B))))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Therefore))
      (, ,)
      (NP (DT the) (JJ anti-CD4) (NN mAb) (CD W3/25))
      (VP (VBD induced)
        (NP
          (NP
            (ADJP (RB only) (JJ weak))
            (NN depletion))
          (PP (IN of)
            (NP (JJ CD4+) (NNS cells))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN indicated)
              (PP (IN by)
                (NP
                  (NP (JJ unchanged) (NNS percentages))
                  (PP (IN of)
                    (NP (JJ CD8+) (NNS cells))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (NN addition)))
    (, ,)
    (NP (EX there))
    (VP (VBD was)
      (NP
        (NP
          (NP (NN modulation))
          (PP (IN of)
            (NP (DT the)
              (NP (NN CD4))
              (CC and)
              (NP (NN co-modulation))))
          (PP (IN of)
            (NP (DT the) (NN CD3) (NN surface) (NNS molecules))))
        (CC and)
        (NP
          (NP (JJ indirect) (NN modulation))
          (PP (IN of)
            (NP (DT the) (NN CD8) (NN molecule)))))
      (PRN (-LRB- -LRB-)
        (S
          (VP (VB see)
            (NP (JJ Supplementary) (NN Table) (NN 2B))))
        (-RRB- -RRB-)))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ anti-CD4) (NN mAb) (NN W3/25))
      (ADVP (RB therefore))
      (VP (VBD represented)
        (NP (DT a)
          (ADJP
            (ADJP
              (ADVP (RB weakly))
              (VBG depleting))
            (, ,)
            (CC but)
            (ADJP (VBG modulating)))
          (NN antibody))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (DT the) (JJ peripheral) (NN blood))
          (PP (IN of)
            (NP (JJ OX35-treated) (NNS rats)))))
      (, ,)
      (NP
        (NP (DT the) (NN percentage))
        (PP (IN of)
          (NP (JJ CD3+) (NNS cells))))
      (VP (VBD was)
        (ADJP
          (ADJP (RB significantly) (JJR lower))
          (PP (IN than)
            (PP (IN in)
              (NP (JJ PBS-treated) (NNS animals)))))
        (PRN (-LRB- -LRB-)
          (S
            (VP (VB see)
              (NP
                (NP (NN Supplementary) (NN Table) (NN 2A))
                (, ,)
                (NP (NN B)))))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN percentage))
        (PP (IN of)
          (NP
            (NP (JJ CD4+) (NNS cells))
            (PP (IN in)
              (NP (DT the) (JJ OX35-treated) (NN group))))))
      (VP (VBD was)
        (ADVP (RB also))
        (ADJP
          (ADJP (RB significantly) (JJR lower))
          (PP (IN than)
            (NP
              (NP (DT that))
              (PP
                (PP (IN of)
                  (NP (DT the) (JJ PBS) (NN control)))
                (, ,)
                (CC both)
                (PP (IN upon)
                  (NP
                    (NP (NN staining))
                    (PP (IN with)
                      (NP
                        (NP (NN W3/25))
                        (CC and)
                        (NP
                          (NP (NN OX35))
                          (PRN (-LRB- -LRB-)
                            (S
                              (VP (VB see)
                                (NP
                                  (NP (NN Supplementary) (NN Table) (NN 2A))
                                  (, ,)
                                  (NP (NN B)))))
                            (-RRB- -RRB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The)
        (ADJP (RB therapeutically) (VBN applied))
        (NN OX35))
      (VP (VBD was)
        (ADVP (RB no) (RBR longer))
        (ADJP (JJ present)
          (PP (IN on)
            (NP
              (NP (DT the) (NNS cells))
              (PP (IN at)
                (NP (DT this) (NN stage))))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN demonstrated)
              (PP (IN by)
                (NP
                  (NP (JJ negative) (NN staining))
                  (PP (IN for)
                    (NP (NN mouse) (NN IgG))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN percentage))
        (PP (IN of)
          (NP
            (NP (JJ CD8+) (NNS cells))
            (PP (IN of)
              (NP (JJ OX35-treated) (NNS rats))))))
      (VP (VBD was)
        (ADVP (CC either)
          (ADVP (RB significantly))
          (CC or)
          (ADVP (RB numerically)))
        (VP (VBN increased)
          (S
            (VP (VBN compared)
              (PP (TO to)
                (NP
                  (NP (DT the) (JJ PBS-treated) (NN control))
                  (PP (IN on)
                    (NP (NN day) (CD 8)
                      (CC or)
                      (CD 13)))))
              (, ,)
              (ADVP (RB respectively)))))))
    (, ,) (IN whereas)
    (S
      (NP
        (NP (DT the) (NN MFI))
        (PP (IN of)
          (NP (DT the) (NN CD8) (NN molecule))))
      (VP (VBD was)
        (ADVP (RB significantly))
        (VP (VBN decreased)
          (PP (IN on)
            (NP (DT both) (NNS days))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (NN comparison))
          (PP (IN with)
            (NP (NN W3/25)))))
      (, ,)
      (NP (DT the) (NN mAb) (NN OX35))
      (VP (VBD induced)
        (NP
          (NP (DT a) (JJR clearer) (NN depletion))
          (PP (IN of)
            (NP
              (NP (JJ CD4+) (NNS cells))
              (PP (IN of)
                (NP (DT the) (JJ peripheral) (NN blood))))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN indicated)
              (PP (IN by)
                (NP
                  (NP (DT a) (JJ significant) (NN increase))
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN percentage))
                      (PP (IN of)
                        (NP (JJ CD8+) (NNS cells))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP (DT the) (NN mAb) (NN OX35))
      (VP (VBD induced)
        (NP
          (NP (NN CD4-modulation))
          (CC and)
          (NP (NN CD3-co-modulation)))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN shown)
              (PP (IN by)
                (NP
                  (NP
                    (NP (DT a) (JJ profound) (NN decrease))
                    (PP (IN of)
                      (NP (JJ CD4+) (NNS cells))))
                  (CC and)
                  (NP
                    (NP (DT a) (NN decrease))
                    (PP (IN of)
                      (NP
                        (NP (DT the) (NN MFI))
                        (PP (IN for)
                          (NP (NN CD4)))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Thus))
      (, ,)
      (NP (NN OX35))
      (VP (VBD represented)
        (NP (DT a)
          (ADJP
            (ADJP (VBG depleting))
            (CC and)
            (ADJP (VBG modulating)))
          (NN antibody))))
    (. .)))

(
  (S
    (S
      (NP (NN RIB5/2))
      (ADVP (RB also))
      (VP (VBD induced)
        (NP
          (NP (DT a) (JJ significant) (NN reduction))
          (PP (IN of)
            (NP (JJ CD3+) (NNS cells)))
          (PP (IN in)
            (NP
              (NP (NN comparison))
              (PP (IN with)
                (NP
                  (NP (DT the) (JJ PBS) (NN group))
                  (PRN (-LRB- -LRB-)
                    (S
                      (VP (VB see)
                        (NP
                          (NP (NN Supplementary) (NN Table) (NN 2A))
                          (, ,)
                          (NP (NN B)))))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN percentage))
        (PP (IN of)
          (NP (JJ CD4+) (NNS cells))))
      (VP (VBD was)
        (ADVP (RB also))
        (ADVP (RB significantly))
        (VP (VBN decreased)
          (PP (IN on)
            (NP (NNS days) (CD 8)
              (CC and)
              (CD 13))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP (EX there))
      (VP (VBD was)
        (NP
          (NP (DT a) (JJ significant) (NN increase))
          (PP (IN of)
            (NP (JJ CD8+) (NNS cells)))
          (PP (IN in)
            (NP
              (NP (DT the) (NN periphery))
              (PP (IN of)
                (NP (JJ RIB5/2-treated) (NNS rats))))))
        (PP (IN in)
          (NP
            (NP (NN comparison))
            (PP (IN with)
              (NP
                (NP (DT the) (JJ PBS-treated) (NN control))
                (PRN (-LRB- -LRB-)
                  (S
                    (VP (VB see)
                      (NP
                        (NP (NN Supplementary) (NN Table) (NN 2A))
                        (, ,)
                        (NP (NN B)))))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Similarly)
        (PP (TO to)
          (NP
            (NP (DT the) (NNS findings))
            (PP (IN for)
              (NP (NN mAb) (CD OX35))))))
      (, ,)
      (NP (NN mAb) (NN RIB5/2))
      (VP (VBD induced)
        (NP
          (NP (NN T-cell) (NN depletion))
          (CC and)
          (NP (NN CD4) (NN modulation)))))
    (: ;)
    (S
      (ADVP (RB however))
      (, ,)
      (NP
        (NP (DT the) (NN degree))
        (PP (IN of)
          (NP (JJ peripheral) (NN T-cell) (NN depletion))))
      (VP (VBD was)
        (ADJP
          (ADJP (JJR stronger))
          (PP (IN than)
            (PP (IN in)
              (NP
                (NP (DT the) (NN case))
                (PP (IN of)
                  (NP (NN OX35)))))))))
    (. .)))

(
  (S
    (ADVP (RB Thus))
    (, ,)
    (SBAR
      (SBAR (IN since)
        (S
          (NP
            (NP
              (ADJP (CC both)
                (ADJP (VBG ameliorating))
                (CC and)
                (ADJP (VBG accelerating)))
              (NNS mAbs))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN OX35))
                (CC and)
                (NP (NN RIB5/2)))
              (-RRB- -RRB-)))
          (VP (VBD depleted)
            (NP (JJ CD4+) (NN T) (NNS cells))
            (PP (IN from)
              (NP (JJ peripheral) (NN blood))))))
      (, ,)
      (CC and)
      (SBAR (IN since)
        (S
          (NP (DT all) (CD three) (NNS mAbs))
          (VP (VBD were)
            (ADJP (JJ modulating))))))
    (, ,)
    (NP (EX there))
    (VP (VBD was)
      (NP
        (NP (DT no) (JJ apparent) (VBP match))
        (PP (IN of)
          (NP (DT these) (NNS parameters))))
      (PP (IN with)
        (NP (DT the) (JJ clinical) (NN efficacy))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Intracellular) (NN staining))
        (PP (IN of)
          (NP
            (NP (NNS cells))
            (VP (VBN preincubated)
              (PP (IN with)
                (NP
                  (NP (JJ anti-CD4) (NNS mAbs))
                  (CC or)
                  (NP (NN isotype) (NNS controls))))))))
      (VP (VBD showed)
        (NP
          (NP (DT a)
            (ADJP (RB uniformly) (JJ high))
            (NN expression))
          (PP (IN for)
            (NP
              (NP (NN IFN-γ))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP
                    (NP
                      (NP (JJ Supplementary) (NNP Fig.) (NN 5a))
                      (, ,)
                      (NP (NN b))
                      (: ;))
                    (PP (IN between)
                      (NP
                        (ADJP
                          (NP
                            (NP (CD 80) (NN %))
                            (CC and)
                            (NP (CD 100) (NN %)))
                          (JJ positive))
                        (NNS cells))))
                  (: ;)
                  (NP (NN MFI)
                    (QP (RB approximately) (CD 30))))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (EX There))
      (VP (VBD were)
        (NP
          (NP (DT no) (NNS differences))
          (PP (IN between)
            (NP (DT the) (JJ anti-CD4)
              (ADJP
                (ADJP (JJ mAb-treated))
                (CC or)
                (ADJP (JJ isotype-treated)))
              (NNS cultures)))
          (PP (IN for)
            (NP
              (NP (DT the) (NN concentration))
              (PP (IN of)
                (NP (NN IFN-γ)))
              (PP (IN in)
                (NP
                  (NP (DT the) (NN supernatant))
                  (PRN (-LRB- -LRB-)
                    (NP (JJ Supplementary) (NNP Fig.) (NN 5c))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ anti-CD4) (NN mAb) (CD W3/25))
      (VP (VBD induced)
        (NP
          (NP (DT a)
            (ADJP (RB significantly) (JJR higher))
            (NN percentage))
          (PP (IN of)
            (NP (JJ IL-4-positive) (NNS cells))))
        (PP (IN at)
          (NP
            (QP (CD 24)
              (CC and)
              (CD 48))
            (NNS hours)))
        (SBAR (IN than)
          (SINV (VBD did)
            (NP (DT the) (NN isotype) (NN control) (-LRB- -LRB-) (NN Supplementary) (NNP Fig.) (CD 5d) (-RRB- -RRB-))))))
    (: ;)
    (S
      (NP (DT the) (NN MFI))
      (VP (VBD was)
        (ADVP (RB also))
        (ADJP
          (ADJP (RB significantly) (JJR higher))
          (PP (IN in)
            (NP
              (NP (NN comparison))
              (PP (IN with)
                (NP
                  (NP
                    (NP (NN OX35))
                    (CC and)
                    (NP (NN RIB5/2)))
                  (PRN (-LRB- -LRB-)
                    (NP (JJ Supplementary) (NNP Fig.) (NN 5e))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (NN contrast)))
    (, ,)
    (NP (EX there))
    (VP (VBD were)
      (NP
        (NP (DT no) (JJ significant) (NNS differences))
        (PP (IN of)
          (NP (DT the) (NN IL-4) (NN concentration)))
        (PP (IN in)
          (NP
            (NP
              (NP (DT the) (NN supernatant))
              (PP (IN of)
                (NP (DT the) (NNS cultures))))
            (PRN (-LRB- -LRB-)
              (NP (JJ Supplementary) (NNP Fig.) (NN 5f))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN observation))
      (VP (MD may)
        (VP (VB be)
          (ADJP (JJ attributable)
            (PP (TO to)
              (NP
                (NP (DT a) (VBN delayed) (NN secretion))
                (PP (IN of)
                  (NP
                    (NP (NN IL-4))
                    (CC or)
                    (NP
                      (NP (NN consumption))
                      (PP (IN of)
                        (NP (DT the) (NN cytokine)))
                      (PP (IN during)
                        (NP (NN culture))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN At)
        (NP (CD 24) (NN h)))
      (, ,)
      (NP
        (NP (DT a) (JJ numerical) (NN increase))
        (PP (IN of)
          (NP
            (NP (DT the) (NN percentage))
            (PP (IN of)
              (NP (JJ IL-10-positive) (NNS cells))))))
      (VP (MD could)
        (VP (VB be)
          (VP (VBN detected)
            (PP (IN after)
              (NP
                (NP (NN preincubation))
                (PP (IN with)
                  (NP
                    (NP (DT the) (JJ ameliorating) (NN mAb) (NN W3/25))
                    (CC and)
                    (NP (DT the) (VBG accelerating) (NN mAb) (NN RIB5/2))))))))))
    (, ,) (IN whereas)
    (S
      (NP
        (NP (DT the) (JJ other) (JJ ameliorating) (NN mAb))
        (, ,)
        (NP (NN OX35))
        (, ,))
      (VP (VBD induced)
        (NP
          (NP (DT a) (JJ significant) (NN increase))
          (PRN (-LRB- -LRB-)
            (NP (JJ Supplementary) (NNP Fig.) (NN 5g))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN increase))
      (VP (VBD was)
        (ADVP (RB no) (RBR longer))
        (VP (VBN observed)
          (PP (IN at)
            (NP
              (NP (CD 48) (NN h))
              (PRN (-LRB- -LRB-)
                (NP (NN Supplementary) (NNP Fig.) (NN 5g))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP
        (NP (DT the) (NN MFI))
        (PP (IN for)
          (NP (NN IL-10))))
      (VP (VBD was)
        (VP (VBN increased)
          (NP (CC both)
            (NP (CD 24) (NN h))
            (CC and)
            (NP (CD 48) (NN h)))
          (PP (IN after)
            (NP
              (NP (NN pretreatment))
              (PP (IN with)
                (NP (JJ anti-CD4) (NNS mAbs))))))))
    (. .)))

(
  (S
    (S
      (S
        (PP (IN At)
          (NP (CD 24) (NN h)))
        (, ,)
        (NP
          (NP (RB only) (DT the) (NN increase))
          (VP (VBN induced)
            (PP (IN by)
              (NP (DT the) (NN mAb) (NN OX35)))))
        (VP (VBD was)
          (ADJP (JJ significant))))
      (, ,)
      (CC but)
      (S
        (PP (IN at)
          (NP (CD 48) (NN h)))
        (NP (DT all) (CD three) (NNS mAbs))
        (VP (VBD induced)
          (NP
            (NP (DT a) (JJ significant) (NN increase))
            (PP (IN of)
              (NP
                (NP (DT the) (NN MFI))
                (PRN (-LRB- -LRB-)
                  (NP (JJ Supplementary) (NNP Fig.) (NN 5h))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Preincubation))
        (PP (IN with)
          (NP (DT all) (JJ anti-CD4) (NNS mAbs))))
      (VP (VBD induced)
        (NP
          (NP (DT a)
            (ADJP (RB significantly) (JJR higher))
            (NN secretion))
          (PP (IN of)
            (NP (NN IL-10))))
        (SBAR (IN than)
          (SINV (VBD did)
            (NP (DT the) (NN isotype) (NN control))))
        (, ,)
        (PP
          (CONJP (RB not) (RB only))
          (PP (IN after)
            (NP (CD 24) (NN h)))
          (, ,)
          (CONJP (CC but)
            (RB also))
          (PP (IN after)
            (NP
              (NP (CD 48) (NNS hours))
              (PRN (-LRB- -LRB-)
                (S
                  (NP (DT the) (JJ latter) (NN increase))
                  (VP (VBD did) (RB not)
                    (VP (VB reach)
                      (NP
                        (NP (JJ statistical) (NN significance))
                        (PP (IN in)
                          (NP
                            (NP (DT the) (NN case))
                            (PP (IN of)
                              (NP (NN OX35)))))))))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (NP
      (NP (NN None))
      (PP (IN of)
        (NP (DT the) (NNS parameters))))
    (, ,)
    (ADVP (RB however))
    (, ,)
    (VP (VBD showed)
      (NP
        (NP (JJ significant) (NNS differences))
        (PP (IN among)
          (NP
            (NP (DT the) (CD three) (JJ different) (JJ anti-CD4) (NNS mAbs))
            (PRN (-LRB- -LRB-)
              (NP (JJ Supplementary) (NNP Fig.) (NN 5i))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN use))
        (PP (IN of)
          (NP (JJ nondepleting) (JJ anti-CD4) (NNS mAbs)))
        (PP (IN for)
          (NP
            (NP (NN treatment))
            (PP (IN of)
              (NP (JJ human) (JJ rheumatoid) (NN arthritis))))))
      (VP (VBZ is)
        (VP (VBG being)
          (VP (VBN discussed)
            (PP (IN at)
              (NP (NN present)))))))
    (: ;)
    (S
      (NP (JJ such) (NN treatment))
      (VP (MD would)
        (VP (VB be)
          (VP (VBN intended)
            (S
              (VP (TO to)
                (VP (VB influence)
                  (NP
                    (NP (DT the) (NN reactivity))
                    (PP (IN of)
                      (NP (JJ CD4+) (NN T) (NNS cells)))))))))
        (, ,)
        (CONJP (RB rather) (IN than))
        (VP (VB remove)
          (NP (PRP them))
          (ADVP (RB completely)))
        (PRN (-LRB- -LRB-)
          (ADVP
            (ADVP (RB particularly))
            (SBAR (IN since)
              (S
                (NP (NN depletion))
                (VP (MD may)
                  (VP (VB induce)
                    (NP (JJ transient) (NN immunodeficiency)))))))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (FW vivo)))
      (, ,)
      (NP
        (NP (DT the)
          (ADJP
            (ADJP (VBG depleting))
            (CC and)
            (ADJP (VBG modulating)))
          (NNS capacities))
        (PP (IN of)
          (NP (DT the) (CD three) (JJ anti-CD4) (NNS mAbs))))
      (VP (VBD were)
        (ADJP (JJ different))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Whereas)
        (S
          (NP (NN W3/25))
          (VP (VBD was)
            (NP (DT a)
              (ADJP
                (ADJP (RB weakly) (VBG depleting))
                (, ,)
                (CC but)
                (ADJP (RB clearly) (VBG modulating))
                (, ,))
              (NN mAb)))))
      (, ,)
      (NP
        (NP (NN RIB5/2))
        (CC and)
        (NP (NN OX35)))
      (VP (VBD were)
        (NP
          (ADJP
            (ADJP
              (ADVP
                (ADVP (RB moderately))
                (CC or)
                (ADVP (RB strongly)))
              (VBG depleting))
            (CC and)
            (ADJP (VBG modulating)))
          (NNS mAbs))
        (, ,)
        (ADVP (RB respectively))))
    (: ;)
    (S
      (NP (DT this) (NN pattern))
      (VP (VBD did) (RB not)
        (VP (VBP match)
          (NP
            (NP (DT the) (NN treatment) (NNS effects))
            (PP (IN of)
              (NP (DT the) (CD three) (NNS mAbs)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ present) (NN study)))
      (, ,)
      (NP (JJ CD4+) (NN T-cell) (NN depletion))
      (VP (VBD was)
        (VP (VBN assessed)
          (PP
            (ADVP (RB only))
            (IN in)
            (NP
              (NP (DT the) (JJ peripheral) (NN blood))
              (, ,)
              (NP
                (NP (DT the) (NN compartment))
                (ADJP (RBS most) (RB easily) (JJ accessible)
                  (PP
                    (ADVP (RB also))
                    (IN in)
                    (NP (NNS humans))))))))))
    (. .)))

(
  (S
    (PP (IN Because)
      (NP
        (NP (NN depletion/modulation))
        (PP (IN in)
          (NP (JJ peripheral) (NN blood)))))
    (VP (MD may)
      (VP (VB differ)
        (PP (IN from)
          (NP
            (NP (DT that))
            (PP (IN in)
              (NP (JJ other) (NNS compartments)))))
        (-LRB- -LRB-)
        (NP (FW e.g.))))))

(
  (S
    (S
      (S
        (NP (JJ lymphoid) (NNS organs))
        (-RRB- -RRB-))
      (, ,)
      (NP
        (NP (DT the) (NN use))
        (PP (IN of)
          (NP
            (NP
              (NP (DT the) (NNS terms))
              (PRN (`` ')
                (NP (VBG depleting))
                ('' ')))
            (CC or)
            (NP (`` ') (NN nondepleting) ('' ')))))
      (VP (VBZ has)
        (S
          (VP (TO to)
            (VP (VB be)
              (ADJP (JJ restricted)
                (PP (TO to)
                  (NP (DT the) (NN blood)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (DT the) (NN case))
          (PP (IN of)
            (NP (DT the) (NNS mAbs)
              (NP
                (NP (CD W3/25))
                (CC and)
                (NP (CD OX35)))))))
      (, ,)
      (ADVP (RB however))
      (, ,)
      (NP
        (NP (NNS studies))
        (PP (IN with)
          (NP
            (ADJP
              (ADJP (JJ marked))
              (, ,)
              (ADJP (JJ antibody-coated)))
            (NNS cells))))
      (VP (VBP indicate)
        (NP
          (NP (DT a) (NN redistribution))
          (PP (IN of)
            (NP (DT the) (NNS cells)))
          (PP (IN from)
            (NP (JJ lymphoid) (NNS organs)))
          (PP (TO to)
            (NP (DT the) (NN liver))))
        (, ,)
        (S
          (ADVP (RB possibly))
          (VP (VBG including)
            (NP
              (NP (NN phagocytosis))
              (CC and)
              (NP
                (NP (NN depletion))
                (PP (IN of)
                  (NP (DT the) (JJ opsonized) (POS ') (NNS cells) (POS ')))
                (PP (IN by)
                  (NP
                    (NP (NN liver) (NNS macrophages))
                    (PRN (-LRB- -LRB-)
                      (NP (JJ unpublished) (NNS observations))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (NP
      (NP (JJ Contrasting) (JJR earlier) (NNS findings))
      (VP (VBG concerning)
        (NP
          (NP (DT the) (VBG depleting) (NN capacity))
          (PP (IN of)
            (NP (DT the) (NN mAb) (NN RIB5/2) (NN -LSB-S7) (, ,) (NN S8) (-RRB- -RSB-))))))
    (VP (MD may)
      (VP (VB be)
        (ADJP (JJ attributable)
          (PP (TO to)
            (NP
              (NP
                (NP (JJ different) (NN time) (NNS points))
                (PP (IN of)
                  (NP (NN investigation))))
              (, ,)
              (NP
                (NP (JJ different) (NNS amounts))
                (PP (IN of)
                  (NP
                    (NP (VBN injected) (NN mAb))
                    (CC or)
                    (NP
                      (NP (NN number))
                      (PP (IN of)
                        (NP (JJ therapeutic) (NNS injections)))))))
              (, ,)
              (CC and)
              (NP
                (NP (JJ different) (JJ experimental) (NNS models))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (JJ personal) (NN communication))
                    (, ,)
                    (NP
                      (NP (NN Dr) (NN M))
                      (NP (NNP Lehmann) (, ,) (NNP University))
                      (PP (IN of)
                        (NP (NN Rostock)))))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Differential) (NNS effects))
        (PP (IN of)
          (NP (DT the) (CD three) (JJ anti-CD4) (NNS mAbs)))
        (PP (IN on)
          (NP (DT the) (JJ mixed) (NN lymphocyte) (NN culture))))
      (VP (VBD were)
        (VP (VBN noted)
          (ADVP (RB only) (RB occasionally))
          (, ,)
          (PP
            (ADVP (RB especially))
            (IN with)
            (NP
              (NP (JJ total) (NN T) (NNS cells))
              (PP (IN as)
                (NP (NNS responders))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (VBG accelerating) (NN mAb) (NN RIB5/2))
      (VP (VBD was)
        (ADVP (RB again))
        (ADJP (RBR more) (JJ effective))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN observation))
        (PP (IN of)
          (NP (JJ differential) (NNS effects)))
        (PP
          (ADVP (RB only))
          (PP (IN with)
            (NP (JJ total) (NN T) (NNS cells)))
          (, ,)
          (CONJP (CC but)
            (RB not))
          (PP (IN in)
            (NP (JJ CD4+) (NN T) (NNS cells)))
          (, ,)))
      (VP
        (VP (VBZ indicates)
          (NP
            (NP (DT a) (JJ differential) (NN contribution))
            (PP (IN of)
              (NP (DT the)
                (ADJP
                  (ADJP (JJ CD4+))
                  (CC and)
                  (ADJP (JJ CD8+)))
                (NN T-cell) (NN subpopulation)))))
        (CC and)
        (VP (VBZ suggests)
          (SBAR (IN that)
            (S
              (NP
                (NP (NNS interactions))
                (PP (IN between)
                  (NP
                    (NP
                      (ADJP
                        (ADJP (JJ CD4+))
                        (CC and)
                        (ADJP (JJ CD8+)))
                      (NN T) (NNS cells))
                    (PRN (NN -LSB-S9) (-RRB- -RSB-)))))
              (VP (VBP are)
                (ADJP (JJ critical)
                  (PP (IN for)
                    (NP
                      (NP (NN T-cell) (NN activation))
                      (CC and)
                      (NP
                        (NP (DT the) (NNS effects))
                        (PP (IN of)
                          (NP (JJ anti-CD4) (NNS mAbs)))
                        (PP (IN on)
                          (NP (DT this) (NN process)))))))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Whereas)
        (S
          (S
            (NP (NN IFN-γ) (NN secretion))
            (VP (VBD was)
              (ADVP (RB completely))
              (VP (VBN unaffected)
                (PP (IN by)
                  (NP (JJ anti-CD4) (NN preincubation))))))
          (CC and)
          (S
            (NP (NN IL-4))
            (VP (VBD was)
              (ADVP (RB only))
              (VP (VBN increased)
                (PP (IN by)
                  (NP (DT the) (NN mAb) (NN W3/25)))
                (PRN (-LRB- -LRB-)
                  (FRAG (RB as)
                    (ADJP (RB previously) (VBN reported))
                    (: ;)
                    (FRAG
                      (NP (NN -LSB-S10))
                      (-RRB- -RSB-)))
                  (-RRB- -RRB-)))))))
      (, ,)
      (NP (NN IL-10) (NN secretion))
      (VP (VBD was)
        (ADVP (RB strikingly))
        (VP (VBN induced)
          (PP (IN by)
            (NP (DT all) (CD three) (JJ anti-CD4) (NNS mAbs))))))
    (. .)))

(
  (S
    (PP
      (ADVP (IN At) (JJS least))
      (IN in)
      (NP
        (NP (DT the) (NN case))
        (PP (IN of)
          (NP (DT the) (JJ ameliorating) (NNS mAbs)
            (NP
              (NP (CD W3/25))
              (CC and)
              (NP (CD OX35)))))))
    (, ,)
    (NP (DT this) (NN effect))
    (VP
      (VP (VBZ is)
        (ADJP (JJ compatible)
          (PP (IN with)
            (NP
              (NP (DT the) (JJ anti-inflammatory) (NN role))
              (PP (IN of)
                (NP (NN IL-10)))
              (PP (IN in)
                (NP
                  (NP (NN arthritis) (CD -LSB-S11))
                  (PRN (, ,)
                    (NP (NN S12))
                    (-RRB- -RSB-))))))))
      (CC and)
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN reported)
            (ADVP (RB also))
            (PP (IN after)
              (NP
                (NP (JJ anti-CD4) (NN therapy))
                (PP (IN in)
                  (NP (NN transplantation) (NN -LSB-S13) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN fact)
        (SBAR (IN that)
          (S
            (NP
              (NP (DT the) (JJ total) (NN number))
              (PP (IN of)
                (NP
                  (ADJP
                    (ADJP (JJ IFN-γ-positive))
                    (CC and)
                    (ADJP (JJ IL-4-/IL-10-positive)))
                  (NN T) (NNS cells))))
            (VP (VBZ exceeds)
              (NP (CD 100) (NN %))))))
      (VP (VBZ indicates)
        (NP
          (NP (DT the) (NN presence))
          (PP (IN of)
            (NP (NN TH0) (NNS cells)))
          (PP (IN in)
            (NP (DT this) (JJ particular) (JJ experimental) (NN system))))))
    (. .)))

(
  (S
    (NP (NNS Abbreviations))))

(
  (S
    (S
      (NP
        (NP
          (NP
            (NP
              (NP
                (NP
                  (NP
                    (NP
                      (NP (NN AA) (JJ =) (NN rat) (JJ adjuvant) (NN arthritis))
                      (: ;)
                      (NP (NN AP-1) (JJ =) (NN activator) (NN protein-1))
                      (: ;)
                      (NP (NN ConA) (JJ =) (NN concanavalin) (NN A))
                      (: ;)
                      (NP (NN DC) (JJ =) (JJ dendritic) (NNS cells))
                      (: ;) (CD DTH))
                    (JJ =) (JJ delayed-type) (NN hypersensitivity))
                  (: ;)
                  (NP (NN ELISA) (JJ =) (JJ enzyme-linked) (JJ immunosorbent) (NN assay))
                  (: ;)
                  (NP (NN FACS) (JJ =) (NN flowcytometry))
                  (: ;)
                  (NP (NN FCS) (JJ =) (JJ fetal) (NN calf) (NN serum))
                  (: ;)
                  (NP (NN FITC) (JJ =) (NN fluorescein) (NN isothiocyanate))
                  (: ;)
                  (NP (NN HEPES) (JJ =) (NN N-)))
                (PRN (-LRB- -LRB-)
                  (NP (NN 2-hydroxyethyl))
                  (-RRB- -RRB-))
                (JJ piperazine-N'-)
                (PRN (-LRB- -LRB-)
                  (NP (JJ 2-ethanesulfonic) (NN acid))
                  (-RRB- -RRB-)))
              (: ;)
              (NP
                (NP
                  (NP (NN IFN) (JJ =) (NN interferon) (: ;) (NN IL) (JJ =) (NN interleukin) (: ;) (NN KA) (JJ =) (NN affinity) (NN constant))
                  (: ;)
                  (NP (NN kass) (JJ =) (NN association) (NN rate) (NN constant))
                  (: ;)
                  (NP
                    (NP (NN kdiss) (JJ =) (NN dissociation) (NN rate) (NN constant))
                    (: ;)
                    (NP (NN mAb) (JJ =) (JJ monoclonal) (NN antibody)))
                  (: ;) (CD MFI))
                (JJ =) (NN mean) (NN fluorescence) (NN intensity))
              (: ;)
              (NP (NN MHC) (JJ =) (JJ major) (NN histocompatibility) (NN complex))
              (: ;)
              (NP
                (NP (NN NF-AT) (JJ =) (JJ nuclear) (NN factor))
                (PP (IN of)
                  (NP (VBN activated) (NN T) (NNS cells))))
              (: ;))
            (NNS PBS))
          (ADJP (JJ =)
            (NP
              (NP (JJ phosphate-buffered) (NN saline))
              (: ;)
              (NP (NN PE) (JJ =) (NN phycoerythrin))
              (: ;)
              (NP (NN PMA) (JJ =) (NN phorbol) (NN myristoyl) (NN acetate))
              (: ;)
              (NP (NN PMSF) (JJ =) (NN phenylmethylsulfonyl) (NN fluoride))
              (: ;)))
          (NN RPMI) (JJ =))
        (NNP Roswell) (NNP Park) (NNP Memorial) (NNP Institute) (NN -LSB-medium) (-RRB- -RSB-)))
    (: ;)
    (S
      (NP (NN SEM))
      (VP (VBG =)
        (NP
          (NP (JJ standard) (NN error))
          (PP (IN of)
            (NP
              (NP (DT the) (NN mean) (: ;) (NN Shc) (JJ =) (NN src-homology-domain-containing-protein))
              (: ;)
              (NP (NN TNF) (JJ =) (NN tumor) (NN necrosis) (NN factor)))))))
    (: ;)
    (S
      (NP (NN TCR))
      (VP (VBG =)
        (NP (NN T-cell) (NN receptor))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure))
      (CC and)
      (NP (NN Table))
      (NP (NNS captions)))))

(
  (S
    (NP
      (NP (NN Figure) (CD 1))
      (: :)
      (NP
        (NP (NN Arthritis) (NN score))
        (PP (IN after)
          (NP
            (NP (JJ preventive) (NN treatment))
            (PP (IN of)
              (NP
                (NP (NN rat) (JJ adjuvant) (NN arthritis))
                (PRN (-LRB- -LRB-)
                  (NP (NN AA))
                  (-RRB- -RRB-))))
            (PP (IN with)
              (NP
                (NP (JJ various) (JJ anti-CD4) (NNS mAbs))
                (CC or)
                (NP
                  (NP (NN PBS) (-LRB- -LRB-) (NNS controls) (-RRB- -RRB-))
                  (PRN (-LRB- -LRB-)
                    (NP (NN means) (NN ±) (NN SEM))
                    (: ;)
                    (S
                      (NP (NN n))
                      (VP (JJ =)
                        (NP (CD 6))
                        (PP (IN for)
                          (NP (DT all) (NNS groups)))))
                    (-RRB- -RRB-))))))))
      (. .))))

(
  (S
    (S
      (NP (NNS Arrows))
      (VP (VBP show)
        (NP
          (NP (DT the) (NNS days))
          (PP (IN of)
            (NP (NN treatment))))
        (PRN (-LRB- -LRB-)
          (NP (NNS days)
            (QP (CD -1) (, ,) (CD 0) (, ,) (CD 3) (, ,) (CD 6)))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Treatment))
        (PP (IN with)
          (NP
            (NP (NN W3/25))
            (CC and)
            (NP (NN OX35)))))
      (ADVP (RB significantly))
      (VP (VBD suppressed)
        (NP
          (NP (NN AA))
          (PP (IN from)
            (NP (NN day) (CD 13))))
        (PP (IN until)
          (NP (NN day) (CD 30)))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP (NN RIB5/2))
      (VP
        (VP (VBD accelerated)
          (NP
            (NP (DT the) (NN onset))
            (PP (IN of)
              (NP (NN AA))))
          (PP (IN by)
            (NP (CD 2) (NNS days))))
        (CC and)
        (VP (VBD led)
          (PP (TO to)
            (NP
              (NP (JJ significant) (NN improvement))
              (PP
                (ADVP (RB only))
                (IN in)
                (NP
                  (NP (DT the) (JJ late) (NN phase))
                  (PRN (-LRB- -LRB-)
                    (PP (IN from)
                      (NP (NN day) (CD 27)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (JJ **) (NN P))
        (VP (JJ ≤)
          (NP (CD 0.01))))
      (, ,)
      (NP (NN *) (NN P))
      (VP (JJ ≤)
        (NP (CD 0.05))
        (, ,)
        (PP (IN in)
          (NP
            (NP (NN comparison))
            (PP (IN with)
              (NP (JJ PBS-treated) (NNS rats)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD One) (NN representative))
        (PP (IN of)
          (NP (CD three) (NNS experiments))))
      (VP (VBZ is)
        (VP (VBN shown))))
    (. .)))

(
  (S
    (NP
      (NP (NN Supplementary) (NN Figure) (CD 1))
      (: :)
      (S
        (NP
          (NP
            (ADJP (FW In) (FW vivo))
            (JJ delayed-type) (NN hypersensitivity))
          (PP (TO to)
            (NP (NN Mycobacterium) (NN tuberculosis))))
        (VP
          (PP (IN on)
            (NP
              (NP (NN day) (CD 13))
              (PP (IN after)
                (NP
                  (NP (JJ preventive) (NN treatment))
                  (PP (IN of)
                    (NP (NN AA)))))
              (, ,)
              (PP (FW i.e.))))
          (SBAR
            (WHADVP (WRB when))
            (S
              (NP
                (NP (DT the) (JJ clinical) (NNS differences))
                (PP (IN between)
                  (NP (DT the)
                    (ADJP
                      (ADJP (VBG accelerating))
                      (CC and)
                      (ADJP (VBG ameliorating)))
                    (JJ anti-CD4) (NNS mAbs))))
              (VP (VBD were)
                (ADJP (JJ maximal)))))))
      (. .))))

(
  (S
    (S
      (NP (DT The) (NNS data))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP
                (NP (NN means))
                (NP
                  (NP (NN ±) (NN SEM))
                  (PRN (-LRB- -LRB-)
                    (S
                      (NP (NN n))
                      (VP (JJ =)
                        (NP
                          (NP
                            (NP (CD 6))
                            (PP (IN for)
                              (NP (DT all) (NNS groups))))
                          (, ,)
                          (NP
                            (NP (CD one) (NN representative))
                            (PP (IN of)
                              (NP (CD three)
                                (ADJP (FW in) (FW vivo))
                                (NNS experiments)))))))
                    (-RRB- -RRB-))))
              (PP (IN of)
                (NP
                  (NP (DT the) (NN difference))
                  (PP (IN between)
                    (NP
                      (NP (DT the) (NN swelling))
                      (PP (IN of)
                        (NP
                          (NP
                            (NP (DT the) (JJ left))
                            (PRN (-LRB- -LRB-)
                              (NP (JJ mycobacterium-treated))
                              (-RRB- -RRB-)))
                          (CC and)
                          (NP (DT the) (JJ right) (-LRB- -LRB-) (JJ PBS-treated) (-RRB- -RRB-) (NNS ears)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN *) (NN P))
      (VP (JJ ≤)
        (NP (CD 0.05))
        (PP (IN in)
          (NP
            (NP (NN comparison))
            (PP (IN with)
              (NP (JJ PBS-treated) (NNS rats)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Supplementary) (NN Figure) (CD 2) (: :)
          (NP
            (NP (NN Concanavalin) (NN A))
            (PRN (-LRB- -LRB-)
              (NP (NN ConA))
              (-RRB- -RRB-)))
          (NN reactivity))
        (PP (IN of)
          (NP
            (NP
              (NP (JJ total) (NN spleen) (NN T) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN day) (CD 13))
                  (PP (IN of)
                    (NP (JJ adjuvant) (NN arthritis))))
                (-RRB- -RRB-)))
            (PP (IN from)
              (NP (NNS rats))))))
      (ADVP (RB preventively))
      (VP (VBN treated)
        (PP (IN with)
          (NP (JJ anti-CD4) (NNS mAbs)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Proliferation) (NNS data))
        (PP (IN from)
          (NP
            (NP (CD two) (JJ individual) (NNS animals))
            (PP (IN of)
              (NP (DT each) (NN treatment) (NN group))))))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (NNS means))
              (VP (VBG ±)
                (NP
                  (NP (NN SEM))
                  (PP (IN of)
                    (NP
                      (NP (JJ triplicate) (NNS cultures))
                      (PP (IN from)
                        (NP (CD one)
                          (ADJP (FW in) (FW vivo))
                          (NN experiment))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ corresponding) (NN arthritis) (NN score))
        (PP (IN for)
          (NP (DT the) (NNS animals))))
      (VP (VBZ is)
        (VP (VBN shown)
          (PP (IN below)
            (NP (DT the) (NN graph))))))
    (. .)))

(
  (S
    (S
      (NP (NN Supplementary) (NN Figure) (CD 4))
      (: :)
      (NP
        (NP
          (NP (JJ Mixed) (NN lymphocyte) (NN culture))
          (PP (IN of)
            (NP
              (NP
                (NP
                  (NP (JJ total))
                  (PRN (-LRB- -LRB-)
                    (NP (NN a))
                    (-RRB- -RRB-)))
                (CC and)
                (NP (JJ CD4+) (-LRB- -LRB-) (NN b) (-RRB- -RRB-) (NN spleen) (NN T) (NNS cells)))
              (PP (IN from)
                (NP (JJ normal) (NN Lewis) (NNS rats)))))
          (PP (IN with)
            (NP
              (NP (JJ different) (NNS densities))
              (PP (IN of)
                (NP (JJ allogeneic) (-LRB- -LRB-) (NN Wistar–Prob) (-RRB- -RRB-) (NN stimulator) (NNS cells)))))
          (, ,)
          (VP (VBN supplemented)
            (PP (IN with)
              (NP
                (NP (NN isotype) (NNS controls))
                (PRN (-LRB- -LRB-)
                  (NP (NN IgG1))
                  (, ,)
                  (NP (NN IgG2a))
                  (-RRB- -RRB-)))))
          (, ,))
        (CC or)
        (NP
          (NP (DT the) (JJ anti-CD4) (NNS mAbs))
          (NP
            (NP (NN W3/25))
            (, ,)
            (NP (NN OX35))
            (, ,)
            (CC and)
            (NP
              (NP (NN RIB5/2))
              (PP (IN at)
                (NP (CD 1) (NN μg/ml))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Data))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (NNS means))
              (VP (VBG ±)
                (NP
                  (NP (NN SEM))
                  (PP (IN of)
                    (NP (DT the) (JJ relative) (NN absorbance))))
                (PP (IN from)
                  (NP
                    (NP (CD three) (JJ independent) (NNS experiments))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NNS triplicates))
                        (PP (IN in)
                          (NP (DT each) (NN experiment))))
                      (-RRB- -RRB-)))))))
          (, ,)
          (S
            (VP (VBN normalized)
              (PP (TO to)
                (NP
                  (NP (DT the) (NN absorbance))
                  (PP (IN of)
                    (NP
                      (NP (JJ PBS-treated) (NNS cultures))
                      (PRN (-LRB- -LRB-)
                        (NP (CD =100) (NN %))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN *) (NN P))
        (VP (JJ ≤)
          (NP (CD 0.05))
          (PP (IN in)
            (NP
              (NP (NN comparison))
              (PP (IN with)
                (NP (DT the) (JJ respective) (NN isotype) (NN control)))))))
      (, ,)
      (S
        (NP (NN #) (NN P))
        (VP (JJ ≤)
          (NP (CD 0.05))
          (PP (IN in)
            (NP
              (NP (NN comparison))
              (PP (IN with)
                (NP
                  (NP (NN W3/25))
                  (, ,)
                  (NP (NN §P) (NN ≤) (CD 0.05))))))
          (PP (IN in)
            (NP
              (NP (NN comparison))
              (PP (IN with)
                (NP (NN OX35))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 2))
      (: :)
      (NP
        (NP (NN Production))
        (PP (IN of)
          (NP (NN TNF-α)))
        (PP (IN by)
          (NP
            (NP (NN spleen) (JJ CD4+) (NN T) (NNS cells))
            (PP (IN after)
              (NP
                (NP (JJ anti-CD4) (NN preincubation))
                (, ,)
                (SBAR (IN as)
                  (S
                    (VP (VBN measured)
                      (PP (IN by)
                        (NP
                          (NP (NN bioassay))
                          (PRN (-LRB- -LRB-)
                            (NP
                              (NP
                                (NP (NN means) (NN ±) (NN SEM))
                                (PP (IN of)
                                  (NP (CD three) (NNS experiments))))
                              (: ;)
                              (NP
                                (NP (JJ pooled) (NN T) (NNS cells))
                                (PP (IN from)
                                  (NP
                                    (NP (CD three) (JJ normal) (NNS rats))
                                    (NP (DT each))))))
                            (-RRB- -RRB-))))))))))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (DT The) (VBG accelerating) (NN mAb))
        (, ,)
        (NP (NN RIB5/2))
        (, ,))
      (VP (VBD induced)
        (NP
          (NP (DT a)
            (ADJP (RB significantly) (JJR stronger))
            (NN increase))
          (PP (IN of)
            (NP (JJ secreted) (NNS TNF-α))))
        (PP (IN than)
          (NP (DT the) (JJ other) (NNS mAbs)))))
    (. .)))

(
  (S
    (S
      (NP (NN Specificity))
      (VP (VBD was)
        (VP (VBN ensured)
          (PP (IN by)
            (S
              (VP (VBG adding)
                (NP (DT a) (NN neutralizing) (NN anti-TNF-α) (NN mAb))
                (PP (TO to)
                  (NP
                    (NP (NNS supernatants))
                    (PP (IN from)
                      (NP (JJ RIB5/2-treated) (NNS cultures)))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN *) (NN P))
      (VP (JJ ≤)
        (NP (CD 0.05))
        (PP (IN in)
          (NP
            (NP (NN comparison))
            (PP (IN with)
              (NP
                (NP (DT the) (NN isotype) (NN control))
                (, ,)
                (NP
                  (NP (NN #) (NN P))
                  (VP (JJ ≤)
                    (NP (CD 0.05))
                    (PP (IN in)
                      (NP
                        (NP (NN comparison))
                        (PP (IN with)
                          (NP
                            (NP (NN W3/25))
                            (, ,)
                            (NP (NN §P) (NN ≤) (CD 0.05))))))
                    (PP (IN in)
                      (NP
                        (NP (NN comparison))
                        (PP (IN with)
                          (NP (NN OX35)))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 3))
      (: :)
      (NP
        (NP
          (NP (NN Electromobility) (NN shift) (NN assay))
          (PRN (-LRB- -LRB-)
            (NP (NN EMSA))
            (-RRB- -RRB-)))
        (PP (IN of)
          (NP
            (NP (JJ nuclear) (NNS extracts))
            (PP (IN from)
              (NP
                (NP (JJ CD4+) (NN T) (NNS cells))
                (PRN (-LRB- -LRB-)
                  (VP
                    (VP (VBN preincubated)
                      (PP (IN with)
                        (NP (JJ anti-CD4) (NNS mAbs))))
                    (CC or)
                    (VP (VBN stimulated)
                      (PP (IN with)
                        (NP (NN PMA/ionomycin)))))
                  (-RRB- -RRB-))))))
        (PP (IN for)
          (NP
            (NP
              (NP (NN AP-1))
              (PRN (-LRB- -LRB-)
                (NP (NN a))
                (-RRB- -RRB-)))
            (CC and)
            (NP
              (NP (NN NF-κB))
              (PRN (-LRB- -LRB-)
                (NP (NN b))
                (-RRB- -RRB-))))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (CD One) (JJ representative) (NN phosphoimage))
        (PP (IN of)
          (NP (CD three) (JJ independent) (NNS experiments))))
      (VP (VBZ is)
        (VP (VBN shown)
          (PRN (-LRB- -LRB-)
            (NP (JJ upper) (NNS panels))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (NP
      (NP (NN Quantification))
      (PP (IN of)
        (NP
          (NP (DT the) (NNS bands))
          (PP (IN of)
            (NP (DT all) (CD three) (NNS experiments))))))
    (VP (VBZ is)
      (VP (VBN shown)
        (PP
          (PP (IN below))
          (PRN (-LRB- -LRB-)
            (NP (NN means) (NN ±) (NN SEM))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (S
        (NP (DT All) (CD three) (JJ anti-CD4) (NNS mAbs))
        (ADVP (RB slightly))
        (VP (VBD decreased)
          (NP (DT the) (NN AP-1) (NN activity))))
      (, ,)
      (CC and)
      (S
        (NP (NN RIB5/2))
        (VP (VBD induced)
          (NP
            (NP (DT a)
              (ADJP
                (ADJP (JJ profound))
                (, ,)
                (ADJP (JJ significant)))
              (NN increase))
            (PP (IN of)
              (NP (JJ NF-κB) (NN activity)))))))
    (. .)))

(
  (S
    (S
      (NP (NN *) (NN P))
      (VP (JJ ≤)
        (NP
          (NP
            (NP (CD 0.05))
            (PP (IN in)
              (NP
                (NP (NN comparison))
                (PP (IN with)
                  (NP
                    (NP (DT the) (NN isotype) (NN control))
                    (, ,)
                    (NP
                      (NP (NN #) (NN P) (NN ≤) (CD 0.05))
                      (PP (IN in)
                        (NP
                          (NP (NN comparison))
                          (PP (IN with)
                            (NP (NN W3/25)))))))))))
          (, ,)
          (NP (CD §P) (NN ≤) (CD 0.05)))
        (PP (IN in)
          (NP
            (NP (NN comparison))
            (PP (IN with)
              (NP
                (NP (NN OX35))
                (, ,)
                (NP (NN &P) (NN ≤) (CD 0.05))))))
        (PP (IN in)
          (NP
            (NP (NN comparison))
            (PP (IN with)
              (NP (NN RIB5/2)))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Supplementary) (NN Figure) (CD 3))
      (: :)
      (NP
        (NP
          (NP
            (NP
              (NP (NN Concanavalin) (NN A))
              (PRN (-LRB- -LRB-)
                (NP (NN ConA))
                (-RRB- -RRB-)))
            (NN reactivity))
          (PRN (-LRB- -LRB-)
            (NP (NN a))
            (-RRB- -RRB-)))
        (PP (IN of)
          (NP
            (NP
              (NP (JJ CD4+) (NN spleen) (NN T) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN day) (CD 13))
                  (PP (IN of)
                    (NP (JJ adjuvant) (NN arthritis))))
                (-RRB- -RRB-)))
            (PP (IN from)
              (NP
                (ADJP (RB preventively) (VBN treated))
                (NNS rats)))))
        (PP (IN with)
          (NP (JJ anti-CD4) (NNS mAbs))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (NN Proliferation) (NNS data))
        (PP (IN from)
          (NP
            (NP (CD two) (JJ individual) (NNS animals))
            (PP (IN of)
              (NP (DT each) (NN group))))))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (NNS means))
              (VP (VBG ±)
                (NP
                  (NP (NN SEM))
                  (PP (IN of)
                    (NP (JJ triplicate) (NNS cultures))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ corresponding) (NN arthritis) (NN score))
        (PP (IN for)
          (NP (DT the) (NNS animals))))
      (VP (VBZ is)
        (VP (VBN shown)
          (PP (IN in)
            (NP (DT the) (NN middle))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN correlation))
        (PP (IN between)
          (NP
            (NP
              (NP (NN reactivity))
              (PP (TO to)
                (NP (NN ConA))))
            (CC and)
            (NP
              (NP (DT the) (NN severity))
              (PP (IN of)
                (NP (NN arthritis)))))))
      (VP (VBZ is)
        (VP (VBN shown)
          (PP (IN in)
            (NP (-LRB- -LRB-) (NN b) (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Normals))
      (VP (VBD =)
        (NP
          (ADJP
            (ADJP (JJ normal))
            (, ,)
            (ADJP (JJ untreated)))
          (NNS rats))))
    (. .)))

(
  (S
    (S
      (NP (NN Supplementary) (NN Figure) (CD 5))
      (: :)
      (NP
        (NP (NN Production))
        (PP (IN of)
          (NP
            (NP
              (NP (NN IFN-γ))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN a))
                  (, ,)
                  (NP (NN b))
                  (, ,)
                  (NP (NN c)))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP (NN IL-4))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN d))
                  (, ,)
                  (NP (NN e))
                  (, ,)
                  (NP (NN f)))
                (-RRB- -RRB-)))
            (, ,)
            (CC and)
            (NP
              (NP (NN IL-10))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN g))
                  (, ,)
                  (NP (NN h))
                  (, ,)
                  (NP (CD i)))
                (-RRB- -RRB-)))))
        (PP (IN by)
          (NP (NN spleen) (JJ CD4+) (NN T) (NNS cells)))
        (PP (IN after)
          (NP (NN anti-CD4-preincubation)))))
    (. .)))

(
  (S
    (NP
      (NP
        (NP
          (NP (NN Percentage))
          (PP (IN of)
            (NP
              (NP (JJ cytokine-positive) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP (JJ upper) (NNS panels))
                (-RRB- -RRB-)))))
        (, ,)
        (NP
          (NP
            (NP (PRP$ their) (NN mean) (NN fluorescence) (NN intensity))
            (PRN (-LRB- -LRB-)
              (NP (CD MFI))
              (-RRB- -RRB-)))
          (PP (IN after)
            (NP
              (NP (JJ intracellular) (NN staining))
              (PRN (-LRB- -LRB-)
                (NP (JJ middle) (NNS panels))
                (-RRB- -RRB-)))))
        (, ,)
        (CC and)
        (NP (NN secretion)))
      (PP (IN of)
        (NP (DT the) (NN cytokine)))
      (PP (IN into)
        (NP (NN cell) (NN culture) (NN supernatant))))
    (PP (IN as)
      (VP (VBN measured)
        (PP (IN by)
          (NP (NN ELISA)))
        (PRN (-LRB- -LRB-)
          (NP (JJR lower) (NNS panels))
          (-RRB- -RRB-))))
    (, ,)
    (VP (VBN shown)
      (PP (IN as)
        (NP
          (NP (NN means) (NN ±) (NN SEM))
          (PP (IN of)
            (NP
              (NP (CD three) (JJ independent) (NNS experiments))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (JJ triplicate) (NNS determinations))
                  (PP (IN in)
                    (NP
                      (NP (JJ pooled) (NNS cells))
                      (PP (IN from)
                        (NP
                          (NP (CD three) (JJ normal) (NNS rats))
                          (PP (IN in)
                            (NP (DT each) (NN experiment))))))))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NN *) (NN P))
      (VP (JJ ≤)
        (NP
          (NP
            (NP (CD 0.05))
            (PP (IN in)
              (NP
                (NP (NN comparison))
                (PP (IN with)
                  (NP (NN isotype) (NN control))))))
          (, ,)
          (NP
            (NP (NN #) (NN P) (NN ≤) (CD 0.05))
            (PP (IN in)
              (NP
                (NP (NN comparison))
                (PP (IN with)
                  (NP
                    (NP (NN W3/25))
                    (, ,)
                    (NP
                      (NP (NN §P) (NN ≤) (CD 0.05))
                      (PP (IN in)
                        (NP
                          (NP (NN comparison))
                          (PP (IN with)
                            (NP (NN OX35))))))
                    (, ,)
                    (NP
                      (NP (NN &P) (NN ≤) (CD 0.05))
                      (PP (IN in)
                        (NP
                          (NP (NN comparison))
                          (PP (IN with)
                            (NP (NN RIB5/2))))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN For)
        (ADJP (JJ key)
          (PP (TO to)
            (NP (NNS bars)))))
      (, ,)
      (VP (VB see)
        (NP (NN Supplementary) (NN Figure) (CD 4))))
    (. .)))

(
  (S
    (NP
      (NP (NN Supplementary) (NN Table) (CD 1))
      (: :)
      (NP
        (NP (NN Affinity) (NN data))
        (PP (IN of)
          (NP (DT the) (JJ anti-CD4) (NN mAb)))))))

(
  (S
    (NP
      (NP (NN Supplementary) (NN Table) (CD 2))
      (: :)
      (NP
        (NP (JJ Cytofluorometric) (NNS analyses))
        (PP (IN of)
          (NP
            (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
            (PP (IN on)
              (NP
                (NP
                  (NP
                    (NP (NN day) (CD 8))
                    (PRN (-LRB- -LRB-)
                      (NP (NN A))
                      (-RRB- -RRB-)))
                  (CC and)
                  (NP
                    (NP (NN day) (CD 13))
                    (PRN (-LRB- -LRB-)
                      (NP (NN B))
                      (-RRB- -RRB-))))
                (PP (IN of)
                  (NP
                    (NP (JJ anti-CD4) (NN treatment))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NNS data))
                        (PP (IN from)
                          (NP
                            (NP (CD one) (NN representative))
                            (PP (IN of)
                              (NP (CD three)
                                (ADJP (FW in) (FW vivo))
                                (NNS experiments))))))
                      (-RRB- -RRB-)))))))))
      (. .))))

